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SUMMARY 
Diffusion magnetic resonance imaging (MRI) is widely used as a research tool to assess (subtle) 
alterations of the cerebral white matter. Measures derived from diffusion MRI appear to be 
valuable markers for cerebral small vessel disease (SVD). However, SVD is frequently co-
occurring with Alzheimer’s disease (AD), and disturbed white matter integrity and altered 
diffusion measures are considered key findings in both conditions. Yet, the contribution of SVD 
and AD to diffusion alterations is unclear, which hampers the interpretation of research studies 
in patients with mixed disease, e.g. memory clinic patients. 
Study 1 of this thesis aimed to clarify the effect of SVD and AD on diffusion measures by 
including multiple (memory clinic) samples covering the entire spectrum of SVD, mixed 
disease, and AD. We calculated diffusion measures from diffusion tensor imaging (DTI) and 
free water imaging. Within each sample of the disease spectrum, we applied simple regression 
analyses and multivariable random forest analyses between AD biomarkers (amyloid-beta, tau), 
conventional MRI markers of SVD, and global diffusion measures. Furthermore, we 
investigated regional associations between tau on positron emission tomography (PET) and 
diffusion measures in voxel-wise analyses. Our main findings are that conventional MRI 
markers of SVD were strongly associated with diffusion measures and showed a higher 
contribution than AD biomarkers in multivariable analyses across all memory clinic samples. 
Regional analyses between tau PET and diffusion measures were not significant. We conclude 
that SVD rather than AD determines diffusion alterations in memory clinic patients. Our 
findings validate diffusion measures as markers for SVD. 
Study 2 applied diffusion MRI markers to study gait impairment in SVD. Gait impairment is a 
commonly reported clinical deficit in SVD patients, but the underlying mechanisms are still 
debated. The proposed mechanisms include SVD-related white matter alterations resulting in 
impaired supraspinal locomotor control, cognitive deficits (e.g. planning and execution of 
movements), and factors independent of SVD, such as age-related instability (e.g. joint wear, 
sarcopenia) and comorbidities (e.g. neurodegenerative pathology). A reason for the lack of 
knowledge on gait impairment in SVD is that studies in elderly, sporadic SVD patients are 
typically confounded by effects of normal-aging and age-related comorbidities. Therefore, 
Study 2 of this thesis aimed to study the effect of pure SVD on gait performance in a relatively 
young sample of genetically defined SVD patients without age-related confounding. We 
performed comprehensive gait assessment using an electronic walkway to obtain multiple 
spatio-temporal gait parameters standardized based on data from healthy controls. Importantly, 
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we tested the association between diffusion MRI markers of SVD-related white matter 
alterations and gait performance, since (strategic) white matter alterations are discussed as a 
major cause of gait decline in the elderly. Furthermore, we assessed the relation between 
cognitive deficits and gait performance. Our main finding is that, despite severe white matter 
alterations in pure SVD patients, gait performance was relatively preserved. Cognitive deficits 
in our study participants were not related to gait impairment. Thus, our results query isolated 
white matter alterations, in the absence of comorbidities, as a main factor of gait impairment in 
SVD and suggest that their combination with age-related comorbidities and/or normal-aging 
may play a crucial role in gait decline. 
In conclusion, diffusion measures are valid MRI markers of SVD-related white matter 
alterations. They have significant value both in future research on altered white matter and 
potentially also in the diagnostic work-up of memory clinic patients, to differentiate between 
vascular and neurodegenerative disease. Researchers may select target populations for clinical 
trials based on diffusion measures, e.g. to identify patients with a low SVD burden as targets 
for prevention and early intervention in SVD. Clinicians and researchers should always 
consider SVD as the origin of diffusion alterations in patients with mixed pathology. The field 
of application of diffusion measures is wide and may provide new insights into effects of subtle 
white matter alterations on clinical deficits, as shown in Study 2 on gait impairment in pure 
SVD. Future studies should investigate measures from advanced diffusion models and 
diffusion-based brain network analysis, to further elucidate the mechanisms of clinical deficits 
in SVD patients. 
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ABBREVIATIONS 
AD Alzheimer’s disease 
Aβ amyloid-beta 
CADASIL cerebral autosomal dominant arteriopathy with subcortical infarcts 
and leukoencephalopathy 
CMB cerebral microbleeds 
CSF cerebrospinal fluid 
DKI diffusion kurtosis imaging 
DTI diffusion tensor imaging 
FA fractional anisotropy 
FAt tissue compartment of FA 
FAu uncorrected FA 
FLAIR fluid-attenuated inversion recovery 
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MDu uncorrected MD 
MRI magnetic resonance imaging 
NODDI neurite orientation dispersion and density imaging 
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1. INTRODUCTION 
Cerebral small vessel disease (SVD), a disorder of the cerebral microvessels, contributes to 
about 50% of all dementias, up to 25% of ischemic strokes, and most hemorrhagic strokes 
(Wardlaw et al., 2019). SVD is present to some extend in more than 90% of individuals aged 
60 or older (de Leeuw et al., 2001). Beside cognitive decline, SVD is associated with various 
clinical deficits, such as gait impairment, depression, and urinary disturbances (Pantoni, 2010). 
Eventually, the disease leads to a complete loss of autonomy in daily living and thus is a 
challenge for our aging society and health-care systems. Comprehensive understanding of the 
disease mechanisms and a reliable diagnosis are inevitable to develop prevention and 
intervention strategies. 
Functionally relevant in vivo disease markers foster the understanding of disease mechanisms 
and improve the diagnosis. Measures derived from diffusion magnetic resonance imaging 
(MRI) appear to be promising markers for SVD-related white matter damage: They capture 
subtle white matter alterations preceding and accompanying the occurrence of visible, 
conventional SVD markers on MRI (e.g. white matter hyperintensities, lacunes), and typically 
outperform conventional SVD markers in explaining clinical deficits and in detecting disease 
progression (Tuladhar et al., 2015; Baykara et al., 2016). However, SVD is frequently co-
occurring with Alzheimer’s disease (AD) in elderly populations (Kapasi et al., 2017), and 
disturbed white matter integrity and altered diffusion measures are considered key findings in 
both conditions (Wardlaw et al., 2013b; Nasrabady et al., 2018). The contribution of SVD and 
AD to diffusion alterations is largely unknown, therefore, diffusion measures as markers for 
white matter alterations appear unspecific for SVD and AD. This research gap was addressed 
in Study 1 of this thesis. Study 2 applied diffusion MRI markers to investigate the role of SVD-
related white matter alterations in gait impairment, a frequently observed clinical deficit in SVD 
patients. 
In the following sections, SVD, its pathology, and conventional SVD markers on MRI are 
briefly introduced. AD as co-existing pathology is described and the challenge to disentangle 
the contribution of SVD and AD to white matter alterations and clinical deficits is pointed out. 
Diffusion measures calculated from two different diffusion MRI models are presented and their 
use in research on white alterations in SVD and AD are reviewed. The lack of knowledge on 
the origin of diffusion alterations is highlighted, which motivated Study 1 (validation of 
diffusion measures as SVD markers). Finally, gait impairment is explored, a common clinical 
deficit in SVD patients and cognitively impaired elderly individuals. Different methods to study 
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gait impairment and its possible mechanisms in SVD patients are summarized. The main causes 
of gait impairment in SVD patients and especially the role of white matter alterations are 
unclear, which motivated Study 2 (application of diffusion MRI markers). 
 
1.1 Pathology and types of cerebral small vessel disease 
The term ‘cerebral small vessel disease’ refers to clinical and imaging abnormalities caused by 
a disorder of the small vessels of the brain, i.e. penetrating arterioles, capillaries, and venules 
(Wardlaw et al., 2019). The exact pathogenesis is still largely unclear, but endothelial 
dysfunction is a potential major initiating event of a pathological cascade. Vessel walls become 
damaged, thickened, and stiff resulting in reduced vasodilation, impaired cerebral blood flow 
(hypoperfusion), and compromised interstitial fluid drainage (fluid stagnation). Eventually, 
these vascular changes will lead to downstream tissue alterations, such as white matter lesions 
visible on conventional MRI, as described in section 1.2.1 (Wardlaw et al., 2013a, 2019). 
SVD is an umbrella term comprising several subtypes. The most common type is typically 
referred to as ‘sporadic SVD’ and mostly related to age and classic vascular risk factors, in 
particular hypertension (ter Telgte et al., 2018). Study 1 includes memory clinic samples of 
sporadic SVD patients with concomitant AD pathology to study the effect of each of these 
conditions on diffusion measures. 
Less common types are inherited, genetically defined forms of SVD, of which the most frequent 
one is cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy (CADASIL) caused by NOTCH3 gene mutations. Lesions visible on 
conventional MRI, as described in section 1.2.1, and clinical characteristics in CADASIL 
mostly resemble those of sporadic SVD patients (Chabriat et al., 2009). CADASIL is 
considered a model disease of pure SVD due to its early disease onset at the age of 35 to 50 
years and the absence of age-related co-pathologies (Chabriat et al., 2009). Study 1 and 2 
include CADASIL patients to study the effect of pure vascular pathology on diffusion measures 
and gait performance. 
Another type of SVD is cerebral amyloid angiopathy, characterized by progressive 
accumulation of amyloid-beta (Aβ) mostly in cortical and leptomeningeal vessels (Bourassa et 
al., 2019) resulting in lobar, i.e. cortical and juxtacortical, macro- and microhemorrhages 
(Knudsen et al., 2001). In contrast, a different lesion pattern is characteristic for sporadic SVD, 
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where mostly deep perforating vessels are affected, resulting in macro- and microhemorrhages 
in deep brain structures, i.e. basal ganglia, thalamus, brain stem, and cerebellum (Wardlaw et 
al., 2013a). A typical imaging feature of cerebral amyloid angiopathy is cortical superficial 
siderosis, a distinct pattern of blood-breakdown product deposition in cortical areas, which is 
rarely found in the elderly population (< 2%) and absent in CADASIL (Linn et al., 2010; 
Charidimou et al., 2015; Wollenweber et al., 2017). As a post-hoc analysis in Study 1, we 
considered the presence of cerebral amyloid angiopathy in a sample of genetically defined AD 
patients. 
 
1.2 Conventional MRI markers of cerebral small vessel disease 
Whereas alterations of the small vessels themselves cannot be detected in vivo in humans with 
current available imaging methods, their pathological consequences, i.e. brain parenchymal 
lesions, are easily recognized on images obtained by conventional MRI. The following sections 
summarize conventional MRI markers of SVD according to the Standards for Reporting 
Vascular Changes on Neuroimaging (STRIVE) criteria (Wardlaw et al., 2013b). In the 
following sections, we point out the advantage of a summary SVD score of several conventional 
MRI markers compared to the use of individual markers, which was used in Study 1 to describe 
SVD burden. 
1.2.1 Individual markers 
White matter hyperintensities (WMHs) are hyperintense signal abnormalities of variable size 
on T2-weighted MRI sequences, e.g. on fluid-attenuated inversion recovery (FLAIR) images 
(Fig. 1A). They are predominantly located in the periventricular and deep white matter and 
mostly reflect demyelination, axonal loss, and gliosis (Wardlaw et al., 2019). WMHs may be 
caused by ischemia or a failure in the clearance of interstitial fluid from the white matter, which 
is associated with blood-brain barrier damage (Weller et al., 2015; Wardlaw et al., 2019). 
Histopathological studies indicate that parietal WMHs may also result from Wallerian 
degeneration due to cortical AD pathology (McAleese et al., 2017). Visual rating scales allow 
to quantify WMH burden, such as the Fazekas scale (Fazekas et al., 1987). WMH volumetry 
describes WMH burden on a continuous scale and is more sensitive for lesion progression than 
visual rating scales (Gouw et al., 2008). 
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Lacunes are fluid-filled round or ovoid subcortical cavities between 3 to about 15 mm in axial 
diameter (Fig. 1B). They appear similar to cerebrospinal fluid (CSF) on MRI and can be 
recognized on FLAIR images. Lacunes most likely result from acute small subcortical infarcts 
or hemorrhages, either symptomatic or silent (ter Telgte et al., 2018). 
Cerebral microbleeds (CMBs) are small depositions of hemosiderin consistent with vascular 
leakage of blood cells into the brain tissue (Fig. 1C). They appear as round, hypointense lesions 
of 2 to 10 mm in diameter on T2*-weighted sequences or susceptibility-weighted imaging (ter 
Telgte et al., 2018). Strictly lobar microbleeds are a feature of cerebral amyloid angiopathy 
(Knudsen et al., 2001). 
Enlarged perivascular spaces (PVS) are enlargements of the spaces around the penetrating 
vessel (Fig. 1D). They are typically located in the basal ganglia and the centrum semiovale and 
follow the course of the vessel with a linear or dot-like shape depending on the view, i.e. parallel 
or perpendicular to the vessel orientation. Usually, PVS measure less than 3 mm in diameter in 
perpendicular view, but can also be larger, especially in the infraputaminal region. PVS are 
visible on T1-weighted (hypointense) or T2-weighted (hyperintense) images and the 
differentiation from lacunes can be challenging (Wardlaw et al., 2013b). 
Recent small subcortical infarcts are hyperintense lesions equal or smaller than 20 mm on 
diffusion MRI images. Subcortical microinfarcts of a size less than 5 mm are detectable only 
with high-resolution imaging, i.e. minimum of 3 Tesla (ter Telgte et al., 2018). 
Cortical microinfarcts are ischemic lesions with a size of only a few millimeters and appear as 
hyperintense lesions on FLAIR and diffusion MRI images. They are best seen in the cortex on 
high-resolution imaging (ter Telgte et al., 2018). 
Brain atrophy describes cortical or subcortical brain volume loss. This marker is not specific 
for SVD as it may occur in many other disorders or conditions, including AD and traumatic 
brain injury (Wardlaw et al., 2013b). 
1.2.2 Summary score 
Most studies rely only on single conventional MRI markers to capture SVD burden. However, 
a score summarizing individual, conventional SVD markers may provide a more 
comprehensive overall view of SVD burden than single markers (Staals et al., 2014). SVD is a 
whole brain disease, as focal lesions occur in white and grey matter and can affect remote brain 
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structures and networks (Duering et al., 2012; Duering et al., 2015; ter Telgte et al., 2018). 
Therefore, in Study 1, complementary to WMH volume (continuous scale), we used an 
established total SVD score (ordinal scale) to quantify SVD burden and to investigate the effect 
of SVD on diffusion measures (Staals et al., 2014). The summary score ranges between 0 and 
4 and captures the severity or presence of WMHs, lacunes, CMBs, and PVS (Fig. 1). These 
four markers show high intercorrelations and are associated with vascular risk factors and 
general cognitive ability (Staals et al., 2014; Staals et al., 2015). 
 
Figure 1. Total cerebral small vessel disease score. The total SVD score summarizes the severity or presence of 
the following conventional MRI markers of SVD on an ordinal scale from 0 to 4 (Staals et al., 2014): (A) WMH 
burden on Fazekas scale 2-3 (1 point), (B) at least one lacune (1 point), (C) at least one CMB (1 point), and (D) 
more than 10 PVS in the basal ganglia on a single T1-weighted axial image slice with the highest number of 
enlarged perivascular spaces (1 point). Abbreviations: CMB = cerebral microbleed; FLASH = fast low angle shot; 
FLAIR = fluid-attenuated inversion recovery; PVS = enlarged perivascular spaces; WMH = white matter 
hyperintensity. 
 
1.3 Alzheimer’s disease as co-existing pathology with cerebral small vessel disease 
AD is a progressive neurodegenerative disorder characterized by extracellular Aβ plaques and 
intracellular tau neurofibrillary tangles (Zetterberg and Mattsson, 2014). Aβ and tau accumulate 
in grey matter and are related to synaptic dysfunction and neuronal loss, which typically 
becomes apparent on conventional MRI as regional and global atrophy including enlarged 
ventricles and decreased hippocampal volume (Selkoe and Hardy, 2016). 
Longitudinal cohort studies increasingly recognized the co-occurrence of SVD and AD (mixed 
disease) in patients with dementia. Data from the Religious Orders Study (Bennett et al., 2013) 
and the Memory and Aging Project (Bennett et al., 2012) indicate that almost 75% of subjects 
(N = 447) with a neuropathologic (ex vivo) diagnosis of AD show concomitant vascular 
Introduction 
 
6 
pathology such as macro- or microinfarcts, atherosclerosis, arteriolosclerosis, or cerebral 
amyloid angiopathy (Kapasi et al., 2017).  
Ex vivo neuropathologic examination is the gold standard for an AD diagnosis (DeTure and 
Dickson, 2019). However, various valid in vivo AD biomarkers are available including CSF 
and PET based assessments of Aβ and pathologic tau: Low concentrations of Aβ1-42 (Aβ 42) in 
CSF indicate cerebral Aβ depositions in the brain tissue (Blennow et al., 2015) and high 
concentrations of tau phosphorylated at threonine 181 (p-tau) in CSF reflect aggregated tau, i.e. 
neurofibrillary tangles (Blennow et al., 2015). CSF total tau (t-tau) is not specific for AD but 
rather a general indicator of neurodegeneration (Wirth et al., 2013). Studies comparing 
neuropathologic examinations and PET imaging validated cortical amyloid PET ligand binding 
as surrogate marker for Aβ deposits in the brain parenchyma and vessel walls (Ikonomovic et 
al., 2008; Clark et al., 2012; Murray et al., 2015) and tau PET ligand binding for pathologic tau 
(Villemagne et al., 2015), although some off-target binding is possible. In Study 2, we used 
CSF and PET based assessments of Aβ and pathologic tau as biomarkers of AD in order to 
investigate the association between AD and diffusion measures. 
 
1.4 Diffusion MRI to assess subtle cerebral white matter alterations 
Diffusion MRI is a technique to study white matter fiber organization in vivo. It captures subtle 
white matter alterations, such as microstructural damage invisible on conventional MRI. In the 
following sections, different measures based on diffusion MRI and their use in research on SVD 
and AD are described. 
1.4.1 Measures from diffusion tensor imaging and free water imaging 
Diffusion MRI characterizes the movement of water molecules in brain tissue. Water diffusion 
in the intracellular space is more restricted than in the extracellular space, because intracellular 
space contains more natural barriers, such as cell membranes and organelles. Water molecules 
within white matter fibers, preferentially diffuse along the fiber direction, i.e. anisotropic 
diffusion, resulting in a higher diffusion coefficient along the fiber compared to diffusion in 
perpendicular directions (Price et al., 2011).  
The most common and most straightforward model for quantifying diffusion and inferring 
tissue architecture from water movement is diffusion tensor imaging (DTI). The three-
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dimensional diffusion in a particular volume element (voxel) can be described by a so-called 
‘tensor’. Frequently used voxel-averaged measures calculated from the tensor are fractional 
anisotropy (FA), reflecting the directionality of water diffusion, and mean diffusivity (MD), 
reflecting the amount of water diffusion. The typical finding in studies on brain pathologies 
affecting the white matter, including SVD and AD, is a decrease in FA and an increase in MD. 
These diffusion alterations were thought to result from microstructural tissue damage, such as 
axonal degeneration (Gouw et al., 2011). However, more recently it has been suggested that 
they may also stem from alterations in extracellular free water content, e.g. through edema 
caused by blood-brain barrier damage (Cognat et al., 2014; Duering et al., 2018). In contrast to 
the simple DTI model, free water imaging, a more complex diffusion model, enables the 
differentiation between free water-related alterations in the brain parenchyma and 
microstructural tissue alterations. 
Free water imaging decomposes the diffusion signal into two compartments, a free water 
compartment (FW), i.e. unrestricted extracellular water diffusion, and a free water corrected 
tissue compartment (Fig. 2) (Pasternak et al., 2009). FW and tissue FA and MD (FAt, MDt) 
are voxel-averaged measures frequently derived from free water imaging. Several studies on 
different brain pathologies, including SVD and AD, indicate that free water imaging sensitively 
captures clinically relevant (subtle) white matter alterations (Pasternak et al., 2009; Pasternak 
et al., 2012; Maier-Hein et al., 2015; Planetta et al., 2015; Duering et al., 2018). Measures from 
DTI and free water imaging were used in Study 1 to investigate their association with SVD and 
AD. 
 
Figure 2. Free water imaging principle. The free water compartment represents water molecules that are not 
restricted or directed. It is modelled by an isotropic tensor with a fixed diffusion coefficient of freely diffusing 
water at 37°C body temperature. The tissue compartment represents all remaining water molecules within or in 
close proximity to cellular structures and is modelled by a unconstrained tensor fit (adapted from Duering et al. 
(2018)). Abbreviations: FAt = tissue compartment of fractional anisotropy; FAu = uncorrected fractional 
anisotropy; FW = free water compartment; MDt = tissue compartment mean diffusivity; MDu = uncorrected mean 
diffusivity. 
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1.4.2 Diffusion alterations in cerebral small vessel disease and Alzheimer’s disease 
In SVD patients, DTI measures outperform conventional MRI markers in explaining cognitive 
deficits and in detecting disease progression (van Norden et al., 2012; Baykara et al., 2016; 
Konieczny et al., 2020). DTI can reveal white matter alterations in SVD, i.e. a decrease in 
uncorrected FA (FAu) and an increase in uncorrected MD (MDu), not only in visibly lesioned 
areas but also in areas with unaltered signal on conventional MRI, i.e. in normal appearing 
white matter. In fact, conventional SVD markers are now known to be only the “tip of the 
iceberg” of the total SVD-related brain damage (ter Telgte et al., 2018). Consequently, diffusion 
measures appear to be highly sensitive markers for SVD burden. However, SVD and AD are 
often concomitant (as described in section 1.3) and subtle white matter alterations have also 
been described in AD. Several studies in sporadic AD patients show that DTI measures are 
associated with AD biomarkers of CSF and PET (Racine et al., 2014; Melah et al., 2016; Hoy 
et al., 2017; Jacobs et al., 2018; Strain et al., 2018; Racine et al., 2019; Vipin et al., 2019; 
Araque Caballero et al., 2020). To date, the contribution of SVD and AD to diffusion alterations 
is unclear, which was addressed in Study 1 of this thesis. 
As mentioned above, the simple DTI model appears unspecific for SVD and AD. Recent 
studies, including one from our group, indicate that free water imaging might be able to 
disentangle SVD- and AD-related subtle white matter alterations (Maier-Hein et al., 2015; 
Duering et al., 2018). We previously showed that diffusion alterations in SVD are 
predominantly driven by an increase in FW, possibly caused by vasogenic edema or 
vacuolization within myelin sheaths, and less by altered fiber geometry, i.e. microstructural 
damage (Duering et al., 2018). Conversely, a study in AD patients suggests that AD pathology 
is mainly represented in free water corrected tissue measures indicating microstructural 
damage. Alterations in the tissue measures were detected in early stages of AD and predicted 
the conversion from mild cognitive impairment to AD dementia (Maier-Hein et al., 2015). Of 
note, free water uncorrected measures, i.e. simple DTI measures, revealed no difference 
between converters from mild cognitive impairment to AD dementia and non-converters. Taken 
together, SVD and AD might have distinct signatures when analyzed with free water imaging. 
We therefore studied associations between SVD, AD, and diffusion measures, not only from 
DTI but also from free water imaging. 
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1.5 Aim Study 1: Validation of diffusion MRI markers 
SVD and AD together cause the majority of dementia cases and are often co-occurring. Both 
diseases are thought to affect the brain’s microstructural white matter integrity. The 
contribution of each of these diseases to subtle white matter alterations is unknown and hampers 
an accurate diagnosis and disease management. Therefore, Study 1 aimed to clarify the 
pathologic contribution of SVD and AD to subtle white matter alterations as assessed by DTI 
and free water imaging, and thereby validate diffusion measures as in vivo markers for SVD 
and/or AD. Additionally, we tested whether SVD and AD have differential effects on measures 
from free water imaging (Maier-Hein et al., 2015; Duering et al., 2018). 
 
1.6 Application of diffusion MRI markers in research on gait impairment in cerebral 
small vessel disease 
White matter alterations in SVD are associated with a variety of clinical deficits including gait 
(walking) impairment. Diffusion measures as sensitive markers for subtle white matter 
alterations are valuable tools to study the effect of SVD burden on gait performance. 
Gait impairment is highly prevalent in the elderly affecting around 35% of individuals aged 70 
or older and more than 46% aged 85 or older (Verghese et al., 2006). These individuals are at 
high risk for falls and fractures, which increase institutionalization and mortality (Bridenbaugh 
and Kressig, 2015; van der Holst et al., 2016). SVD in the elderly appears to play an important 
role in the development of gait impairment. After cognitive disturbances, gait impairment is the 
second most common clinical deficit in SVD (Okroglic et al., 2013). Yet, relative to the number 
of studies on cognitive disturbances, studies on gait impairment in SVD are scarce and the 
etiology of gait impairment is still unclear. Therefore, there is an urgent need to identify the 
underlying mechanisms of gait impairment in SVD in order to develop prevention, intervention, 
and rehabilitation strategies. 
In the following sections, methods of gait assessment used in Study 2 are introduced and 
possible contributing factors of gait impairment in SVD are discussed. 
1.6.1 Gait assessment 
The assessment of gait and balance can be useful in the diagnostic work-up, because specific 
features of gait are characteristic for different diseases. For instance, gait characteristics of SVD 
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patients with diffuse white matter alterations are small steps, wide-based gait, and variable 
timing and amplitude of steps, whereas Parkinson’s disease patients with affected substantia 
nigra often show narrow-based gait and freezing of gait (Snijders et al., 2007). Clinical 
assessment most commonly includes visual observation during ordinary gait, typically while 
walking in the corridor. Standard rating scales allow to score gait and balance, e.g. the Tinetti 
mobility index (Tinetti, 1986). However, observational gait assessment requires training and 
clinical experience. While quantitative screening test, e.g. the Timed-Up-and-Go (Podsiadlo 
and Richardson, 1991) and the Short Physical Performance Battery (Guralnik et al., 1994), 
capture gait velocity and balance with high reliability, these tests do not allow to evaluate gait 
quality. In contrast, advanced tools, such as pressure-sensitive insoles or pressure-sensitive 
carpets record multiple spatio-temporal gait parameters and automatically evaluate gait 
performance, independent of a time-consuming subjective rating. Despite being cost-intensive, 
these advanced tools enable comprehensive gait analysis with high concurrent validity and test-
retest reliability and foster standardized methodology of research on gait impairment (Bilney et 
al., 2003; Menz et al., 2004). Therefore, in Study 2, gait parameters were assessed using a 
computerized walkway (GAITRite, MAP/CIR Inc. Havertown, PA, USA). 
1.6.2 Factors of gait impairment in cerebral small vessel disease 
Various factors of gait impairment in SVD patients have been described in previous research 
(Fig. 3). First, altered white matter is considered an important contributor to gait decline in 
SVD as indicated by associations between conventional MRI markers of SVD and gait 
performance (de Laat et al., 2010b; de Laat et al., 2011; Smith et al., 2015; Pinter et al., 2017). 
Compared to conventional MRI markers, stronger associations can be found with diffusion 
measures as markers of subtle white matter alterations in SVD (Van Der Holst et al., 2018). 
Some studies described strategic white matter regions to be associated with gait impairment, 
such as the internal capsule, bilateral frontal periventricular white matter, and the corpus 
callosum, especially the genu (de Laat et al., 2010a; Srikanth et al., 2010; Van Der Holst et al., 
2018). 
Second, more recently, cognitive deficits have been related to gait impairment. Normal walking 
relies on the interaction of various cognitive functions, including executive control, i.e. 
planning and execution of movements, and postural control (Snijders et al., 2007). Studies using 
the so-called ‘dual task paradigm’ indicate that the ability to maintain normal walking 
deteriorates while performing a secondary cognitive task. The demands of walking and the 
secondary task are thought to exceed limited cognitive resources resulting in gait decline, 
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specifically in cognitively impaired individuals, who are not able to cognitively compensate 
gait difficulties (Muir et al., 2012). In Study 2, we implemented two different cognitively 
challenging dual task conditions, to study the effect of cognition on gait. 
Third, age-related instability, such as degenerative, musculoskeletal disorders or comorbidities 
such as neurodegenerative disease or vestibular dysfunction, independent of SVD, may directly 
affect gait (Aboutorabi et al., 2016). Other consequences of normal-aging, such as visual or 
oculomotor changes, are considered as indirect causes of gait decline, when forcing individuals 
to walk more cautiously, e.g. by reducing stride length and velocity (Bridenbaugh and Kressig, 
2015). 
A reason for the lack of knowledge on mechanisms of gait impairment in SVD is that gait 
studies typically include elderly SVD patients (aged 60 years or older). Results may therefore 
be confounded by effects of normal-aging and age-related comorbidities. In Study 2, to shed 
more light onto pure SVD-related effects on gait performance, we studied CADASIL patients 
with genetically defined SVD, with a high SVD burden already at young age (for details on 
CADASIL see section 1.1). 
 
Figure 3. Factors influencing gait impairment in sporadic cerebral small vessel disease. SVD- and age-related 
factors may contribute to gait impairment in SVD patients (adapted from Snijders et al. (2007)). Abbreviations: 
AD = Alzheimer’s disease; SVD = cerebral small vessel disease. 
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1.7 Aim Study 2: Studying the effect of pure cerebral small vessel disease on gait 
The etiology of gait impairment in SVD is largely unclear. SVD-related white matter alterations 
and cognitive deficits, as well as age-related instabilities and comorbidities might foster gait 
impairment in SVD (Fig. 3). Study 2 aimed to examine the effect of pure SVD without age-
related confounding on gait performance by studying CADASIL patients (for details on 
CADASIL see section 1.1). These patients have a high SVD burden already at young age. 
Importantly, we applied diffusion measures, which have been validated in Study 1 as markers 
for subtle SVD-related white matter alterations, to investigate the association between disturbed 
white matter and gait. Also, we aimed to study the association between cognitive deficits, i.e. 
processing speed as the main cognitive deficit in SVD, and gait.  
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2. STUDIES 
This chapter comprises two research articles on the validation (Study 1) and application (Study 
2) of diffusion MRI markers. The original numbering of tables, figures, and supplementary 
material within each article has been retained. 
 
2.1 Study 1: Validation of diffusion MRI markers 
The following section includes the research article entitled “Small vessel disease rather than 
Alzheimer’s disease determines diffusion MRI alterations in memory clinic patients”. The 
manuscript has been submitted to a journal and is currently under review. 
Small vessel disease rather than Alzheimer’s disease determines diffusion MRI alterations in 
memory clinic patients 
Sofia Finsterwalder, MSc1* Naomi Vlegels, MSc2* Benno Gesierich, PhD1 Miguel Á. Araque 
Caballero, PhD1,3 Nick A. Weaver, MD2 Nicolai Franzmeier, PhD1 Marios K. Georgakis, MD,1 
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DELCODE study group,** Frank Jessen, MD11,12 Emrah Düzel, MD13,14 Laura Dobisch, 
MSc13,14 Coraline Metzger, MD, PhD13,14,15 Oliver Peters, MD16,17 Enise I. Incesoy, MD17 Josef 
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2.1.1 Abstract 
Introduction: Microstructural alterations as assessed by diffusion tensor imaging (DTI) are key 
findings in both Alzheimer’s disease (AD) and small vessel disease (SVD). We determined the 
contribution of each of these conditions to diffusion alterations. 
Methods: We studied six samples (N = 365 participants) covering the spectrum of AD and 
SVD, including genetically defined samples. We calculated diffusion measures from DTI and 
free water imaging. Simple linear, multivariable random forest, and voxel-based regressions 
were used to evaluate associations between AD biomarkers (amyloid-beta, tau), SVD imaging 
markers, and diffusion measures. 
Results: SVD markers were strongly associated with diffusion measures and showed a higher 
contribution than AD biomarkers in multivariable analysis across all memory clinic samples. 
Voxel-wise analyses between tau and diffusion measures were not significant. 
Discussion: In memory clinic patients, the effect of SVD on diffusion alterations largely 
exceeds the effect of AD, supporting the value of diffusion measures as markers of SVD.  
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2.1.2 Introduction 
Alzheimer’s disease (AD) and cerebral small vessel disease (SVD) are the two leading causes 
of cognitive decline and dementia (O'Brien and Thomas, 2015). Altered white matter 
microstructure is considered a key finding in both conditions (Wardlaw et al., 2013; Nasrabady 
et al., 2018) and has consistently been associated with cognitive deficits (Baykara et al., 2016; 
Araque Caballero et al., 2018; Mito et al., 2018). The most commonly used method to study 
white matter microstructure in vivo is diffusion tensor imaging (DTI), which quantifies 
diffusion properties of water molecules in brain tissue (Amlien and Fjell, 2014; Pasi et al., 
2016). The typical finding described in both AD and SVD is an increase in the extent of water 
diffusion (mean diffusivity) and a decrease in diffusion directionality (fractional anisotropy). 
Despite the wide use of diffusion alterations as efficient disease markers and their strong 
associations with clinical deficits, little is known about their underlying pathology (Tuladhar et 
al., 2015; Baykara et al., 2016; Araque Caballero et al., 2018). 
In memory clinic patients, AD and SVD often co-exist (Kapasi et al., 2017). The extent to 
which each of these conditions contribute to diffusion alterations is largely unknown and has 
so far not been examined in a systematic study covering the entire spectrum of AD, mixed 
disease, and SVD. Free water imaging, an advanced diffusion model, improves the specificity 
of the DTI model and could therefore provide additional insight into the origin of diffusion 
magnetic resonance imaging (MRI) alterations (Pasternak et al., 2009). Recent studies suggest 
that by modelling two distinct diffusion compartments, free water imaging might be suited to 
disentangle the effects of AD and SVD (Maier-Hein et al., 2015; Hoy et al., 2017; Duering et 
al., 2018; Vipin et al., 2019). 
The aim of this study was to determine the contribution of AD and SVD to microstructural 
alterations as assessed by diffusion MRI, using conventional DTI and free water imaging. We 
examined associations between biomarkers of AD, MRI markers of SVD, and diffusion 
measures. Six study samples (N = 365 participants) were included to cover the entire spectrum 
of AD, mixed disease, and SVD, and to account for both cerebrospinal fluid (CSF) and positron 
emission tomography (PET) markers. Analyses were performed separately within each sample 
in order to validate results and address generalizability using the independently recruited 
samples. Our analysis also included patient samples with pure, genetically defined AD or SVD, 
which enabled us to examine effects of both diseases on diffusion measures without 
confounding pathology. 
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2.1.3 Methods 
Participants 
We studied six independent samples (N = 365 participants) covering the spectrum of AD, mixed 
disease, and SVD: four memory clinic samples with mixed disease with a recruitment focus on 
either AD or SVD, one sample each of genetically defined AD and SVD. Memory clinic 
samples were drawn from single or multi-center studies, which were selected based on 
availability of (diffusion) MRI sequences and CSF or PET data. The compilation of samples, 
subject selection criteria, and exclusions are shown in Fig. 1, and further elaborated below. 
MRI, CSF, and PET data from subjects of the included samples were obtained within one year. 
Diagnostic criteria used in the AD and SVD focused memory clinic samples are summarized 
in Supplementary Table 1. All studies were approved by the ethics committees of the 
respective institutions and all subjects provided written informed consent. 
 
Figure 1. Study concept and participant selection flowchart. Samples cover the entire spectrum of AD, mixed 
disease, and SVD. Abbreviations: AD = Alzheimer’s disease; DTI = diffusion tensor imaging; EYO = estimated 
years from symptom onset; FLAIR = fluid-attenuated inversion recovery; p-tau = phosphorylated-tau181; SVD = 
small vessel disease; t-tau = total tau. 
 
Alzheimer’s disease focused samples 
We included 89 participants from the German multicentric DZNE-Longitudinal Cognitive 
Impairment and Dementia Study (DELCODE; downloaded in December 2018) with available 
CSF amyloid-beta1-40 (Aβ 40), amyloid-beta1-42 (Aβ 42), total-tau (t-tau), and phosphorylated- 
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tau181 (p-tau) data. The sample consisted of Aβ 42-positive healthy controls (Aβ 42 cut-off see 
Supplementary Text 1) and patients with subjective cognitive decline, amnestic mild cognitive 
impairment, and mild dementia (Jessen et al., 2018). 
We further included 53 participants from the multicentric Alzheimer’s disease Neuroimaging 
Initiative (ADNI, phase 3; downloaded in December 2018 at http://adni.loni.usc.edu) with 
available Aβ [18F]-florbetapir and tau [18F]AV-1451 flortaucipir (PET). The sample consisted 
of amyloid-positive (cut-off see Supplementary Text 1) healthy controls and patients with 
amnestic mild cognitive impairment and mild dementia (http://adni.loni.usc.edu). 
Small vessel disease focused samples 
We included 39 participants from the University Medical Center Utrecht, Netherlands 
(prospective Utrecht Vascular Cognitive Impairment study, UVCI) with available CSF data for 
Aβ 42, t-tau, and p-tau. The sample consisted of patients with subjective cognitive decline, mild 
cognitive impairment, and dementia and with no evidence of a primary etiology other than 
neurodegenerative disease or sporadic SVD and a high burden of SVD on MRI (Aalten et al., 
2014). 
We further included 39 participants from the Samsung Medical Center, Seoul, Republic of 
Korea (Seoul Vascular Cognitive Impairment study, SVCI) with available Aβ [18F]-florbetaben 
and tau [18F]AV-1451 flortaucipir (PET). The sample consisted of patients with objective 
cognitive impairment and a high burden of SVD on MRI (Kim et al., 2016; Kim et al., 2018). 
Genetically defined samples 
As a genetically defined AD sample, we included 77 participants from the multicentric 
Dominantly Inherited Alzheimer Network (DIAN, data freeze 11; downloaded in August 
2018).(Moulder et al., 2013) DIAN is a longitudinal cohort study of individuals at risk of 
developing autosomal dominant AD. Here we included PSEN1 (n = 59), PSEN2 (n = 5), and 
APP (n = 13) mutation carriers with available Aβ 40, Aβ 42, t-tau, and p-tau CSF data. In our 
study, subjects had to be less than 15 years from estimated symptom onset in order to increase 
sensitivity to detect AD and SVD marker alterations in proximity to the onset of AD symptoms 
(Fleisher et al., 2015; Araque Caballero et al., 2018). 
As a genetically defined SVD sample, we included 68 patients with Cerebral Autosomal 
Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) 
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recruited from a single-center study in Munich (Baykara et al., 2016). Although CSF or PET 
data were not available in this dataset, we included CADASIL to judge the effect sizes of SVD 
markers in genetically defined SVD. 
MRI 
All MRI data were obtained on 3 Tesla systems. All samples included diffusion MRI, T1-
weighted, fluid-attenuated inversion recovery (T2-weighted), and gradient echo (T2*-
weighted) sequences. While each study used a standardized protocol, acquisition parameters 
differed across studies. The MRI protocols have been published previously for DIAN (Araque 
Caballero et al., 2018), DELCODE (Franzmeier et al., 2019), ADNI (Jiaerken et al., 2018), 
UVCI (Heinen et al., 2018), SVCI (Kim et al., 2016), and CADASIL (Duering et al., 2018). 
Diffusion MRI sequence parameters for all samples are summarized in Supplementary 
Table 2. All diffusion images were processed with the same pipeline as described in 
Supplementary Text 2. Global diffusion measures were calculated as mean of all voxels within 
a white matter skeleton. Regional analyses were based on voxel-wise diffusion measures. 
Alzheimer’s disease markers 
We used Aβ and tau (CSF or PET) as biomarkers of AD. Details on CSF assays, PET tracers, 
and calculations of PET standardized uptake value ratio (SUVR) scores have previously been 
published for DIAN (Araque Caballero et al., 2018), DELCODE (Jessen et al., 2018), ADNI 
(http://adni.loni.usc.edu), UVCI (de Wilde et al., 2017), and SVCI (Kim et al., 2018). 
For the main analyses we used continuous CSF and PET measures. For a subgroup analysis in 
amyloid-positive individuals, we used study specific Aβ cut-off values. See Supplementary 
Text 1 for details. 
Small vessel disease markers 
We used an established total SVD score (ordinal variable) (Staals et al., 2014) and white matter 
hyperintensity (WMH) volume (continuous variable) as MRI markers of SVD. The total SVD 
score summarizes the presence or severity of SVD lesions on an ordinal scale, i.e. WMH, 
lacunes, microbleeds, and enlarged perivascular spaces (Staals et al., 2014). Two trained raters 
(SF, NV) assessed these lesions according to the STRIVE consensus criteria (Wardlaw et al., 
2013): WMHs were rated using the Fazekas scale (Fazekas et al., 1987), the number of lacunes 
was determined on fluid-attenuated inversion recovery and T1-weighted images, the number of 
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cerebral microbleeds on T2*-weighted gradient echo images, and the number of enlarged 
perivascular spaces in the basal ganglia on a single T1-weighted axial image slice with the 
highest number of perivascular spaces (Potter et al., 2015). WMH volume was calculated from 
a previously described semi-automated segmentation pipeline (Baykara et al., 2016). 
Statistical analyses 
All statistical analyses were performed in R (version 3.5.1) (R Core Team, 2013). The statistical 
significance level was set at 𝛼𝛼 < 0.05. 
Associations between AD biomarkers, SVD markers, age, and sex (independent variables), and 
global diffusion measures (dependent variables) were first assessed by simple linear regression 
analyses within each sample. Variables were power transformed in case of non-normal 
distribution (Shapiro-Wilk test) (Yeo and Johnson, 2000). 
To perform multivariable analysis in the presence of multicollinearity, i.e. intercorrelations 
among disease markers (Supplementary Figure 1), we used random forest regressions (R 
package ‘party’; version 1.3-2) (Strobl et al., 2007). This method allows to assess the 
contribution of each AD biomarker, SVD marker, age, and sex to diffusion alterations, while 
accounting for all other variables. For each sample, we calculated 1501 conditional inference 
trees with unbiased variable selection and default parameters as previously described (Duering 
et al., 2018). We calculated conditional variable importance together with a 95% confidence 
interval from 100 repetitions. 
An effect of Aβ on diffusion measures might be mediated by vascular pathology, in particular 
cerebral amyloid angiopathy, i.e. Aβ accumulation in perforating vessels (Charidimou et al., 
2017). To address this possibility, we performed a post-hoc mediation analysis (R package 
‘lavaan’; version 0.6-4) (Rosseel, 2012) in samples where simple regression analysis showed 
an effect of Aβ on diffusion measures. Diffusion measures were entered as dependent variables, 
Aβ as independent variable, WMH volume as mediator, and age as covariate. Standard errors 
were based on bootstrapping (1000 iterations). 
Because amyloid pathology has been shown to strengthen the association between tau 
accumulation and structural tract alterations as assessed by diffusion measures (Jacobs et al., 
2018), we performed two additional analyses within each sample. First, we conducted a 
sensitivity analysis restricted to amyloid-positive individuals by repeating simple regression 
analyses. Second, we assessed the interaction effect of tau ´ Aβ on diffusion measures. 
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Finally, since tau is a localized pathology starting in the entorhinal cortex (Cho et al., 2016), 
we also performed regional analyses between voxel-wise diffusion measures and tau in the PET 
samples, i.e. ADNI and SVCI. We used permutation test theory with a standard general linear 
model as implemented in ‘randomise’ (FSL). We assessed associations between both global tau 
PET SUVR scores as well as regional tau PET SUVR scores in the entorhinal cortex and voxel-
wise diffusion measures. The number of permutations was set at 5000. Significant voxels within 
the skeletonized diffusion measure maps were identified using threshold-free cluster 
enhancement with P < 0.05, corrected for multiple comparisons. 
2.1.4 Results 
Sample characteristics are summarized in Table 1. As expected, patients with genetically 
defined AD or SVD were considerably younger than memory clinic patients.  
Small vessel disease shows stronger associations than Alzheimer’s disease with diffusion 
alterations in simple regression analyses 
In simple regressions, both SVD markers, i.e. WMH volume and total SVD score, were 
consistently and strongly associated with conventional DTI measures (FAu, MDu; range of 
R2adj. [0.08 – 0.79]) and FW (range of R2adj. [0.18 – 0.76]) across all six samples (Fig. 2, 
Supplementary Tables 3-5). In contrast, AD biomarkers, i.e. CSF and PET data, were not or 
only weakly associated with conventional DTI measures and FW (range of R2adj. [0.04 – 0.18]; 
Fig. 2, Supplementary Tables 3-5). Results were largely consistent across study samples, with 
a notable exception in the sample of genetically defined AD (DIAN). Here, effect sizes for Aβ 
42 (CSF) were similar to the effect sizes of WMH volume (Fig. 2, Supplementary Table 5). 
Associations between Aβ 42, WMH volume and diffusion measures in DIAN and DELCODE 
were further addressed in a post-hoc mediation analysis (see below). 
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Table 1. Sample characteristics. 
 
For numeric variables median (interquartile range) [min, max] is shown, except for age. a DELCODE: CDR of 1 
subject missing. Abbreviations: AD = Alzheimer’s disease; CDR = clinical dementia rating; FAu = uncorrected 
fractional anisotropy; DTI = diffusion tensor imaging; FAt = free water corrected tissue compartment of fractional 
anisotropy; FW = free water content; HC = healthy control; MCI = mild cognitive impairment; MDu = uncorrected 
mean diffusivity; MDt = free water corrected tissue compartment of mean diffusivity; na = not available; p-tau = 
phosphorylated- tau181; SCD = subjective cognitive decline; SUVR = standardised uptake value ratio; SVD = small 
vessel disease; SVD score = total small vessel disease score; t-tau = total tau; WMHvol = white matter 
hyperintensity volume. 
 
 
 
  Genetically 
defined AD 
 AD 
focused 
 SVD 
focused 
 Genetically 
defined SVD 
  DIAN (n = 77)  DELCODE (n = 89)  ADNI (n = 53)  UVCI (n = 39)  SVCI (n = 39)  CADASIL (n = 68) 
             
Age, years  42 (14)  72 (9)  78 (13)  74 (12)  79 (10)  55 (11) 
Female, n (%)  40 (52)  36 (40)  25 (47)  13 (33)  28 (72)  44 (65) 
Diagnosis, n (%) 
HC, SCD, MCI, dementia  
 na  4 (4), 37 (42),  
33 (37), 15 (17) 
 22 (42), na,  
23 (43), 8 (15) 
 0 (0), 3 (8),  
18 (46), 18 (46) 
 0 (0), na,  
22 (56), 17 (44) 
 na 
CDR, n (%) 
0, 0.5, 1, 2, 3  
 38 (49), 29 (38), 9 (12),  
1 (1), 0 (0) 
 29 (33), 52 (59), 7 (8), 
0 (0), 0 (0)a 
 22 (42), 23 (43), 6 (11),  
2 (4), 0 (0) 
 1 (3), 30 (77), 8 (20),  
0 (0), 0 (0) 
 0 (0), 26 (67), 7 (18),  
6 (15), 0 (0) 
 57 (84), 9 (13), 1 (1),  
1 (1), 0 (0) 
Aβ positive, n (%)  46 (60)  44 (49)  37 (70)  22 (56)  19 (49)  na 
DTI             
FAu, mm2/s  0.45 (0.03) [0.38, 0.49]  0.46 (0.03) [0.36, 0.52]  0.45 (0.04) [0.38, 0.50]  0.44 (0.04) [0.36, 0.48]  0.42 (0.04) [0.35, 0.50]  0.40 (0.06) [0.27, 0.49] 
MDu, 10-4 mm2/s   7.84 (0.64) [7.27, 9.31]  7.68 (0.59) [6.71, 9.72]  8.21 (0.63) [7.35, 9.77]  8.05 (0.82) [7.23, 9.72]  9.66 (0.76) [8.48, 11.0]  9.40 (1.61) [7.79, 12.89] 
FAt, mm2/s  0.55 (0.02) [0.52, 0.58]  0.56 (0.02) [0.52, 0.60]  0.57 (0.02) [0.54, 0.60]  0.56 (0.02) [0.52, 0.57]  0.59 (0.01) [0.56, 0.63]  0.55 (0.02) [0.50, 0.59] 
MDt, 10-4 mm2/s  5.92 (0.07) [5.80, 6.01]  5.97 (0.10) [5.51, 6.14]  6.01 (0.63) [5.94, 6.09]  5.82 (0.15) [5.63, 5.99]  6.00 (0.04) [5.91, 6.12]  5.97 (0.03) [5.89, 6.03] 
FW, mm2/s  0.18 (0.05) [0.14, 0.28]  0.16 (0.04) [0.11, 0.29]  0.20 (0.05) [0.13, 0.31]  0.22 (0.06) [0.16, 0.35]  0.25 (0.04) [0.17, 0.31]  0.29 (0.11) [0.17, 0.51] 
AD markers             
CSF             
Aβ 40, ng/L  7634 (4516) [2215, 15622]  7942 (3229) [3721, 13358]  -  na  -  - 
Aβ 42, ng/L  436 (332) [174, 1424]  498 (380) [183, 1317]  -  619 (279) [363, 1641]  -  - 
T-tau, ng/L  97 (132) [8, 563]  425 (369) [98, 1477]  -  524 (368) [140, 1274]  -  - 
P-tau, ng/L  56 (66) [14, 163]  51 (39) [16, 192]  -  67 (47) [19, 166]  -  - 
PET             
[18F]-florbetapir SUVR  -  -  1.18 (0.36) [0.90, 1.70]  -  na  - 
[18F]-florbetaben SUVR  -  -  na  -  1.38 (0.49) [1.11, 2.17]  - 
[18F]AV-1451 SUVR  -  -  1.10 (0.13) [0.86, 1.67]  -  1.11 (0.16) [0.89, 1.60]  - 
SVD markers             
WMHvol, ml  2.22 (3.05)  
[0.00, 30.47] 
 2.78 (5.36)  
[0.03, 34.50] 
 3.35 (8.29)  
[0.00, 77.24] 
 15.72 (1.85)  
[1.34, 67.27] 
 32.19 (21.03)  
[10.48, 71.20] 
 71.27 (73.74)  
[1.09, 257.74] 
SVD score, n (%) 
0, 1, 2, 3, 4 
 67 (87), 9 (12), 1 (1),  
0 (0), 0 (0) 
 23 (26), 33 (37), 28 (31),  
3 (3), 2 (2) 
 8 (15), 17 (32), 18 (34),  
8 (15), 2 (4) 
 4 (10), 15 (39), 11 (28),  
6 (15), 3 (8) 
 0 (0), 0 (0), 0 (0),  
0 (0), 39 (100) 
 0 (0), 16 (24), 19 (28),  
17 (25), 16 (24) 
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Figure 2. Simple regression analyses. Simple linear regression analyses between diffusion measures and AD 
biomarkers or SVD markers. Standardized β is represented by color. Abbreviations: AD = Alzheimer’s disease; βs 
= standardized beta; FAu = uncorrected fractional anisotropy; FAt = free water corrected tissue compartment of 
fractional anisotropy; FW = free water content; MDu = uncorrected mean diffusivity; MDt = free water corrected 
tissue compartment of mean diffusivity; np = not possible (all patients had the maximum score); ns = not 
significant; p-tau = phosphorylated- tau181; SVD = small vessel disease; SVD score = total small vessel disease 
score; t-tau = total tau; WMHvol = white matter hyperintensity volume. 
 
Small vessel disease and age contribute most to diffusion alterations in multivariable analyses 
Using random forest regression as a multivariable method, we assessed the contribution of each 
AD biomarker, SVD marker, age and sex to diffusion measures, while accounting for 
multicollinearity. In all memory clinic samples, SVD markers showed higher variable 
importance than AD biomarkers for alterations of conventional DTI measures (FAu and MDu; 
Fig. 3) and FW (data not shown; nearly identical to MDu). The opposite was found only in 
DIAN, where AD biomarkers showed higher variable importance. For tissue measures (FAt 
and MDt), interpretation of random forest regressions was not feasible, because variable 
importances were zero or almost zero in all samples (data not shown). 
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Figure 3. Multivariable analyses. Random forest regression analyses for estimating the relative variable 
importance of AD biomarkers (grey bars), SVD markers (black bars), age and sex (white bars) with regard to 
conventional DTI measures (FAu, MDu) while accounting for all other variables (conditional importance). Lines 
indicate the 95% confidence interval for the conditional variable importance. Abbreviations: AD = Alzheimer’s 
disease; FAu = uncorrected fractional anisotropy; MDu = uncorrected mean diffusivity; p-tau = phosphorylated-
tau181; SVD = small vessel disease; SVD score = total small vessel disease score; T-tau = total tau; WMHvol = 
white matter hyperintensity volume. 
 
White matter hyperintensities partially mediate the effect of Aβ on diffusion alterations in 
genetically defined Alzheimer’s disease  
For diffusion measures significantly associated with Aβ 42 (CSF) in the simple regression 
analysis, i.e. in DIAN and DELCODE, we performed a post-hoc mediation analysis to explore 
whether these associations might be mediated by vascular pathology, such as cerebral amyloid 
angiopathy. In DIAN, the effect of Aβ 42 on MDu and FW was indeed partially mediated by 
WMH volume (MDu: βs = -0.06, SE = 0.03, P = 0.030; FW: βs = -0.06, SE = 0.03, P = 0.026). 
However, we also found a direct effect of Aβ 42 on MDu and FW (MDu: βs = -0.30, SE = 0.12, 
P = 0.005; FW: βs = -0.30, SE = 0.11, P = 0.005). For FAu, mediation analysis was not 
significant. In DELCODE, where simple regression analysis showed only weak effects of 
Aβ 42, none of the mediation analyses were significant (all P > 0.136). 
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Tau is not associated with diffusion alterations in amyloid-positive individuals 
It was recently reported that Aβ might strengthen the association between tau accumulation and 
diffusion alterations (Jacobs et al., 2018). We addressed this aspect in a sensitivity analysis 
restricted to amyloid-positive individuals (see Table 1 for subsample sizes). Simple linear 
regressions between tau and diffusion measures in amyloid-positive individuals were not 
significant, except for DIAN (n = 46; p-tau and MDu, βs = 0.32, R2adj. = 0.08, P = 0.031; p-tau 
and FW, βs = 0.31, R2adj. = 0.07, P = 0.038). In correspondence with the full DIAN sample, tau 
showed effect sizes comparable to those found for WMH volume (WMH volume and MDu, 
βs = 0.35, R2adj. = 0.10, P = 0.017; WMH volume and FW, βs = 0.37, R2adj. = 0.12, P = 0.011). 
None of the tau ´ Aβ interaction models with diffusion measures as dependent variables were 
significant in any of the samples (all P > 0.051). 
Regional tau is not associated with diffusion alterations 
Tau is a localized pathology starting in the entorhinal cortex (Cho et al., 2016) and previous 
literature suggests localized effects of tau on white matter microstructure (Kantarci et al., 2017; 
Jacobs et al., 2018; Strain et al., 2018). We therefore performed regional analyses in the PET 
samples, i.e. ADNI and SVCI, which allow to assess local tau load. Associations between 
regional tau PET SUVR scores in the entorhinal cortex or global tau PET SUVR scores and 
voxel-wise diffusion measures were not significant. 
2.1.5 Discussion 
We investigated the effect of AD and SVD on brain microstructure assessed by diffusion 
measures. As a unique feature, our study included six independently recruited samples covering 
the entire spectrum of AD, mixed disease, and SVD. The main finding is that in memory clinic 
patients SVD rather than AD determines diffusion alterations. Results were consistent across 
all memory clinic samples, illustrating the robustness and generalizability of our findings. 
The strong effect of SVD on diffusion measures was evident in all of the six study samples. In 
contrast, an association between AD and diffusion measures was only detectable in DELCODE 
and DIAN. While in DELCODE effect sizes of AD biomarkers were considerably smaller than 
those of SVD markers, effect sizes of Aβ 42 and WMH volume were similar in DIAN. 
Multivariable analyses using random forest regression showed a higher importance of SVD 
markers for diffusion alterations in all memory clinic samples. The only sample in which AD 
biomarkers had a higher variable importance was DIAN. As expected for a genetically defined 
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sample, these patients are considerably younger than typical memory clinic patients and less 
likely to show age-related comorbidities, such as SVD. Still, mediation analysis in DIAN 
suggested a vascular contribution to diffusion alterations also in this population, as the effect 
of Aβ on diffusion alterations was partly mediated by WMH volume. This might indicate a 
contribution of cerebral amyloid angiopathy, a specific subtype of SVD caused by deposition 
of Aβ in perforating vessels (Charidimou et al., 2017). Overall, we conclude that while the 
effect of AD on diffusion measures is apparent in DIAN patients with pure AD, the presence 
of SVD in the other samples masks the effect of AD on diffusion measures. 
Seemingly in contrast with our results, associations between AD biomarkers and alterations of 
white matter microstructure as assessed by DTI have been previously reported in memory clinic 
patients (Racine et al., 2014; Melah et al., 2016; Hoy et al., 2017; Jacobs et al., 2018; Strain et 
al., 2018; Racine et al., 2019; Vipin et al., 2019), although some studies found no association 
(Kantarci et al., 2014; Pietroboni et al., 2018). Importantly, however, only one of these studies 
accounted for SVD. Hence, the effect of AD on diffusion alterations might have been 
overestimated. Only Strain et al. (2018) considered biomarkers of both diseases and found an 
association between tau PET (but not Aβ PET) in temporal regions and diffusion measures in 
temporal white matter projections, independently of WMHs. In line with our results, the effect 
size for WMH volume was larger than effect sizes of AD biomarkers. By considering both 
diseases, we conclude that SVD determines diffusion alterations to a much larger extent than 
AD, even in samples where AD was the clinically predominant disease. The strong effect of 
SVD has implications for future studies, which will need to take SVD into account as an 
important confounder. 
In the current study, neither the regional analysis nor the analysis in amyloid-positive 
individuals, where the effect of tau was expected to be stronger (Jacobs et al., 2018), indicated 
a significant association between tau and diffusion measures. In post-mortem studies, white 
matter alterations in AD patients have been attributed to axonal degeneration secondary to 
cortical deposition of hyperphosphorylated tau (McAleese et al., 2015; McAleese et al., 2017). 
Yet, post-mortem studies by design examine patients in very late stages of AD, while our 
memory clinic patients were mostly in earlier disease stages. Thus, it is conceivable that our 
patients have not yet reached the disease stage where associations between tau and axonal 
degeneration can be detected. 
Our finding that diffusion alterations are predominantly driven by SVD is also supported by a 
genome-wide association study in the population-based UK Biobank. Polygenic risk scores for 
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altered DTI measures were associated with SVD-related stroke and major depressive disorder, 
but not with AD (Rutten-Jacobs et al., 2018). The study thus provided genetic evidence that 
mechanisms underlying diffusion alterations are shared with cerebrovascular disease. 
Another aim of this study was to investigate whether free water imaging allows to disentangle 
the contribution of SVD and AD. The finding that SVD markers showed strongest associations 
with FW corroborates previous results indicating that diffusion alterations in SVD patients are 
predominantly driven by an increase in the free water content (Duering et al., 2018). However, 
our current analysis did not provide evidence that AD biomarkers are reflected in the tissue 
compartment. The latter result is in contrast to studies suggesting that AD-related 
neurodegeneration of the white matter might be specifically represented in free water corrected 
tissue measures: Tissue measures were associated with conversion from mild cognitive 
impairment to dementia in AD patients (Maier-Hein et al., 2015) and showed Aβ-related 
longitudinal changes (Vipin et al., 2019). It should be noted that the current study was cross-
sectional and thus we cannot exclude that the tissue compartment holds valuable information 
for longitudinal studies (Maier-Hein et al., 2015; Vipin et al., 2019). 
A limitation of our study is that elevated tau (especially in CSF) is not specific for AD as it 
could also indicate other tauopathies, such as Pick’s disease, corticobasal degeneration, or 
progressive supranuclear palsy. However, the tau PET tracer ([18F]AV-1451) employed mostly 
binds to tau deposits specific for AD (Lowe et al., 2016). Also, the focus on recruitment of 
clinical AD, e.g. by including amnestic mild cognitive impairment in DELCODE and ADNI, 
clearly enriched for AD rather than other tauopathies. Another limitation is the lack of AD 
biomarkers in the CADASIL sample. Yet, the purpose of the CADASIL sample was to judge 
the effect sizes of SVD markers in genetically defined disease, i.e. in young patients with pure 
SVD. Interestingly, we found similar effect sizes as in SVD focused samples with mixed 
pathology, in particular the UVCI sample. As a further limitation, multi-shell diffusion data, 
which would be necessary for more complex parametrization of the fluid compartments (Hoy 
et al., 2014; Rydhög et al., 2017; Sepehrband et al., 2019) was not available in the study 
samples. 
The main strength of our analysis is the inclusion of multiple samples from different countries 
and ethnicities, covering the entire spectrum of AD, mixed disease, and SVD. This has enabled 
us to independently validate results and to assess both CSF and PET biomarkers of AD in a 
robust manner. The differences in study protocols among the six samples, such as MRI 
acquisition, biomarker assessment techniques, and recruitment strategies suggest that our 
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results are generalizable to other populations along the spectrum of AD and SVD. We also 
included younger individuals with genetically defined disease to minimize confounding by 
other age-related pathologies. Finally, the state-of-the art diffusion imaging analysis pipeline 
included modern pre-processing techniques and rigorous control for confounding by CSF 
partial volume effects, which is crucial in patients with atrophy and therefore enlarged CSF 
spaces. 
In conclusion, we demonstrate that SVD rather than AD determines diffusion alterations in 
memory clinic patients. Our results validate diffusion measures as markers for SVD and as 
valuable tools to assess the vascular contribution to AD and dementia, which still needs to be 
adequately explored (Sweeney et al., 2019). Building upon our findings, future studies could 
assess if more advanced parameterization of diffusion processes, such as biophysical diffusion 
models, further increases the sensitivity in earlier or even asymptomatic stages. 
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2.1.9 Supplementary material 
Supplementary Table 1. Diagnostic criteria in memory clinic samples 
 
aJessen F, Spottke A, Boecker H, et al. Design and first baseline data of the DZNE multicenter observational study 
on predementia Alzheimer’s disease (DELCODE). Alzheimers Res Ther. 2018;10(1):15; 
bhttp://adni.loni.usc.edu; cAalten P, Ramakers IHGB, Biessels GJ, et al. The Dutch Parelsnoer Institute-
Neurodegenerative diseases; methods, design and baseline results. BMC neurol. 2014;14(1):254; dKim HJ, Yang 
JJ, Kwon H, et al. Relative impact of amyloid-β, lacunes, and downstream imaging markers on cognitive 
trajectories. Brain. 2016;139(9):2516-27; eKim HJ, Park S, Cho H, et al. Assessment of extent and role of tau in 
subcortical vascular cognitive impairment using 18F-AV1451 positron emission tomography imaging. JAMA 
neurol. 2018;75(8):999-1007. Abbreviations: AD = Alzheimer’s disease; CERAD = Consortium to Establish a 
Registry for Alzheimer’s disease; CDR = clinical dementia rating; CSF = cerebrospinal fluid; ELISA = enzyme-
linked immunosorbent assays; HC = cognitively healthy control; MCI = mild cognitive impairment; MMSE = 
Mini-Mental-State Examination; na = not available; NIA-AA = National Institute on Aging research criteria for 
probable AD; NINCDS-ADRDA = National Institute of Neurological and Communicative Disorders and Stroke 
and the AD and Related Disorders Association; PET = positron emission tomography; SCD = subjective cognitive 
decline; SUVR = standardized uptake value ratio; SD = standard deviation; SVD = small vessel disease. 
 
Supplementary Table 2. Diffusion parameters 
 
Abbreviations: TE = echo time; TR = repetition time. 
         
 
  AD 
focused 
 SVD 
focused 
  DELCODEa  ADNI, phase 3b  UVCc  SVCId,e 
HC  No subjective/ objective cognitive 
decline 
 MMSE ≥ 24;  
CDR = 0 
 na  na 
SCD  Subjectively reported cognitive 
worsening; age-, sex-, and 
education-adjusted CERAD 
neuropsychological test  
battery > -1.5 SD 
 na  Subjective cognitive decline; no 
objective cognitive impairment on 
a standardized neuropsychological 
test battery 
 na 
MCI  Age-, sex-, and education-adjusted 
performance CERAD episodic 
memory tests < -1.5 SD 
 Subjective memory complaints 
without significant functional 
impairment; MMSE ≥ 24; 
objective memory impairment on 
the revised Wechsler Memory 
Scale; CDR = 0.5; memory  
CDR  ≥ 0.5. 
 Subjective and objective cognitive 
decline in at least one cognitive 
domain without significant 
functional impairment 
 Objective memory decline below 
the 16th percentile (- 1.0 SD) of 
age- and education-matched 
norms in at least one cognitive 
domain tested by the Seoul 
Neuropsychological Screening 
Battery; Petersen’s criteria 
Dementia  NIA-AA for probable AD;  
MMSE ≥ 18 
 NINCDS-ADRDA criteria  NINCDS-ADRDA criteria  NIA-AA for probable AD 
 
                              
  
                      
                       
                              
                              
                            
                           
                 
     
 
 
 
 
 
 
 
 
 
 
 
        
  
 DIAN DELCODE ADNI UVCI SVCI CADASIL 
Scanner Siemens  
systems 
Siemens  
systems 
GE Healthcare 
systems 
Philips  
Achieva 
Philips 
Achieva 
Siemens  
Verio 
TR [ms] 11000 12100 7200 6600 7696 12700 
TE [ms] 87 88 56 73 60 81 
Slice [mm] 2.50 2.00 2.00 2.50 2.00 2.00 
In-plane [mm] 2.50 x 2.50 2.00 x 2.00 2.00 x 2.00 1.72 x 1.72 1.72 x 1.72 2.00 x 2.00 
b-value [s/mm2] 1000 700, 1000 1000 1200 600 1000 
Directions 64 30, 30 48 45 45 30 
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Supplementary Table 3. Simple regression models in Alzheimer’s disease focused samples 
 
 
P < 0.05 in bold. Abbreviations: βs = standardised beta; FAu = uncorrected fractional anisotropy; FAt = free water 
corrected tissue compartment of fractional anisotropy; FW = free water content; MDu = uncorrected mean 
diffusivity; MDt = free water corrected tissue compartment of mean diffusivity; P-tau = phosphorylated-tau181; 
R2adj. = adjusted explained variance; SVD score = total small vessel disease score; T-tau = total tau; WMHvol = 
white matter hyperintensity volume. 
Supplementary Table 4. Simple regression models in small vessel disease focused samples 
 
 
P < 0.05 in bold. Abbreviations: βs = standardised beta; FAu = uncorrected fractional anisotropy; FAt = free water 
corrected tissue compartment of fractional anisotropy; FW = free water content; MDu = uncorrected mean 
diffusivity; MDt = free water corrected tissue compartment of mean diffusivity; np = not possible (all patients had 
the maximum score); P-tau = phospho-tau181; R2adj. = adjusted explained variance; SVD score = total small vessel 
disease score; T-tau = total tau; WMHvol = white matter hyperintensity volume. 
           
  FAu      MDu      FAt      MDt      FW      
 βs R2adj. P  βs R2adj. P  βs R2adj. P  βs R2adj. P  βs R2adj. P  
DELCODE (n = 89)                    
Age -0.38 0.13 0.000  0.42 0.17 0.000  -0.21 0.03 0.051  0.15 0.01 0.171  0.49 0.23 0.000  
Sex (f-m) -0.52 0.05 0.016  0.28 0.01 0.198  -0.69 0.11 0.001  0.11 -0.01 0.599  0.23 0.00 0.279  
Aβ 40 (CSF) 0.04 -0.01 0.745  -0.03 -0.01 0.770  0.07 -0.01 0.492  0.00 -0.01 0.963  0.00 -0.01 0.969  
Aβ 42 (CSF) 0.17 0.02 0.102  -0.23 0.04 0.029  0.09 0.00 0.386  -0.11 0.00 0.314  -0.24 0.05 0.025  
T-tau (CSF) -0.25 0.05 0.019  0.29 0.07 0.005  -0.14 0.01 0.201  0.16 0.02 0.123  0.33 0.10 0.002  
P-tau (CSF) -0.20 0.03 0.063  0.23 0.04 0.033  -0.09 0.00 0.405  0.13 0.00 0.238  0.27 0.06 0.009  
WMHvol -0.30 0.08 0.004  0.40 0.15 0.000  -0.05 -0.01 0.631  0.14 0.01 0.206  0.47 0.21 0.000  
SVD score -0.32 0.09 0.002  0.41 0.16 0.000  -0.14 0.01 0.206  0.18 0.02 0.088  0.44 0.18 0.000  
ADNI (n = 53)                    
Age -0.35 0.10 0.011  0.49 0.23 0.000  0.10 -0.01 0.464  0.10 -0.01 0.476  0.51 0.24 0.000  
Sex (f-m) -0.21 -0.01 0.460  0.42 0.03 0.125  0.28 0.00 0.322  0.29 0.00 0.301  0.39 0.02 0.158  
Aβ (PET) 0.14 0.00 0.312  -0.07 -0.02 0.635  0.23 0.04 0.091  -0.19 0.02 0.164  -0.05 -0.02 0.744  
Tau (PET) 0.05 -0.02 0.745  -0.04 -0.02 0.777  0.02 -0.02 0.875  0.14 0.00 0.323  -0.05 -0.02 0.702  
WMHvol -0.43 0.17 0.001  0.58 0.32 0.000  0.12 0.00 0.376  0.10 -0.01 0.490  0.62 0.38 0.000  
SVD score -0.38 0.12 0.006  0.43 0.17 0.001  -0.02 -0.02 0.863  0.26 0.05 0.061  0.45 0.19 0.001  
     
                      
                   
                       
  
            
 
  FAu      MDu      FAt      MDt      FW      
 βs R2adj. P  βs R2adj. P  βs R2adj. P  βs R2adj. P  βs R2adj. P  
UVCI (n = 39)                    
Age -0.46 0.19 0.003  0.49 0.22 0.002  -0.32 0.08 0.050  0.33 0.09 0.039  0.49 0.22 0.002  
Sex (f-m) 0.15 0.00 0.363  -0.08 -0.02 0.607  0.22 0.02 0.177  -0.21 0.02 0.199  -0.11 -0.02 0.518  
Aβ 42 (CSF) 0.02 -0.03 0.923  -0.18 0.01 0.262  -0.24 0.03 0.135  -0.03 -0.03 0.850  -0.18 0.01 0.262  
T-tau (CSF) 0.21 0.02 0.207  -0.07 -0.02 0.678  0.32 0.08 0.044  -0.08 -0.02 0.632  -0.05 -0.02 0.743  
P-tau (CSF) 0.16 0.00 0.334  -0.07 -0.02 0.651  0.23 0.03 0.159  -0.08 -0.02 0.604  -0.05 -0.02 0.760  
WMHvol -0.80 0.62 0.000  0.85 0.72 0.000  -0.50 0.23 0.001  0.62 0.37 0.000  0.85 0.71 0.000  
SVD score -0.59 0.33 0.000  0.62 0.37 0.000  -0.39 0.13 0.013  0.46 0.19 0.003  0.62 0.36 0.000  
SVCI (n = 39)                    
Age -0.16 0.00 0.333  0.11 -0.02 0.521  -0.18 0.01 0.279  0.08 -0.02 0.616  0.11 -0.01 0.490  
Sex (f-m) 0.05 -0.03 0.894  -0.03 -0.03 0.943  0.04 -0.03 0.902  0.36 0.00 0.323  -0.05 -0.03 0.888  
Aβ (PET) -0.27 0.05 0.093  0.30 0.06 0.068  -0.11 -0.01 0.505  0.19 0.01 0.244  0.30 0.06 0.064  
Tau (PET) -0.11 -0.01 0.499  0.09 -0.02 0.572  -0.06 -0.02 0.729  0.10 -0.02 0.529  0.09 -0.02 0.579  
WMHvol -0.49 0.22 0.001  0.58 0.32 0.000  -0.17 0.00 0.288  0.37 0.11 0.022  0.57 0.31 0.000  
SVD score np np np  np np np  np np np  np np np  np np np  
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Supplementary Table 5. Simple regression models in genetically defined samples  
 
 
P < 0.05 in bold. Abbreviation: βs = standardised beta; FAu = uncorrected fractional anisotropy; FAt = free water 
corrected tissue compartment of fractional anisotropy; FW = free water content; MDu = uncorrected mean 
diffusivity; MDt = free water corrected tissue compartment of mean diffusivity; P-tau = phosphorylated-tau181; 
R2adj. = adjusted explained variance; SVD score = total small vessel disease score; T-tau = total tau; WMHvol = 
white matter hyperintensity volume. 
 
Supplementary Table 6. DIAN consortium 
Last Name First Affiliation 
Allegri Ricardo FLENI Institute of Neurological Research (Fundacion para la Lucha 
contra las Enfermedades Neurologicas de la Infancia) 
Bateman  Randy Washington University in St. Louis School of Medicine 
Bechara Jacob Neuroscience Research Australia 
Benzinger Tammie Washington University in St. Louis School of Medicine 
Berman Sarah University of Pittsburgh 
Bodge Courtney Brown University-Butler Hospital 
Brandon Susan Washington University in St. Louis School of Medicine 
Brooks William (Bill) Neuroscience Research Australia 
Buck Jill Indiana University 
Buckles Virginia Washington University in St. Louis School of Medicine 
Chea Sochenda Mayo Clinic Jacksonville 
Chhatwal Jasmeer  Brigham and Women’s Hospital–Massachusetts General Hospital 
Chrem Patricio FLENI Institute of Neurological Research (Fundacion para la Lucha 
contra las Enfermedades Neurologicas de la Infancia) 
Chui Helena University of Southern California 
Cinco Jake University College London 
Clifford Jack Mayo Clinic Jacksonville 
Cruchaga Carlos Washington University in St. Louis School of Medicine 
Donahue Tamara Washington University in St. Louis School of Medicine 
Douglas Jane University College London 
           
 
  FAu      MDu      FAt      MDt      FW      
 βs R2adj. P  βs R2adj. P  βs R2adj. P  βs R2adj. P  βs R2adj. P  
DIAN (n = 77)                    
Age -0.38 0.13 0.001  0.35 0.11 0.002  -0.27 0.06 0.018  0.05 -0.01 0.669  0.37 0.12 0.001  
Sex (f-m) 0.25 0.00 0.267  0.06 -0.01 0.805  0.58 0.07 0.010  0.44 0.04 0.055  0.05 -0.01 0.821  
Aβ 40 (CSF) 0.08 -0.01 0.468  -0.08 -0.01 0.468  0.07 -0.01 0.564  -0.07 -0.01 0.555  -0.07 -0.01 0.522  
Aβ 42 (CSF) 0.41 0.16 0.000  -0.43 0.17 0.000  0.22 0.03 0.057  -0.18 -0.01 0.053  -0.43 0.18 0.000  
T-tau (CSF) -0.26 0.05 0.024  0.33 0.10 0.003  -0.09 0.00 0.427  0.14 0.01 0.228  0.32 0.09 0.004  
P-tau (CSF) -0.23 0.04 0.047  0.37 0.12 0.001  0.01 -0.01 0.918  0.21 0.04 0.056  0.36 0.12 0.001  
WMHvol -0.35 0.11 0.002  0.45 0.20 0.000  -0.08 -0.01 0.484  0.42 0.17 0.000  0.47 0.21 0.000  
SVD score -0.18 0.02 0.113  0.16 0.01 0.157  -0.11 0.00 0.345  0.13 0.00 0.255  0.18 0.02 0.115  
CADASIL (n = 68)                    
Age -0.51 0.25 0.000  0.56 0.30 0.000  -0.42 0.16 0.000  0.02 -0.01 0.888  0.52 0.26 0.000  
Sex (f-m) -0.19 -0.01 0.450  0.28 0.00 0.267  -0.03 -0.01 0.900  -0.47 0.04 0.064  0.25 0.00 0.322  
WMHvol -0.84 0.71 0.000  0.89 0.79 0.000  -0.71 0.49 0.000  0.39 0.14 0.001  0.87 0.76 0.000  
SVD score -0.55 0.29 0.000  0.54 0.28 0.000  -0.54 0.28 0.000  0.02 -0.01 0.878  0.52 0.26 0.000  
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Edigo Noelia FLENI Institute of Neurological Research (Fundacion para la Lucha 
contra las Enfermedades Neurologicas de la Infancia) 
Erekin-Taner Nilufer Mayo Clinic Jacksonville 
Fagan Anne Washington University in St. Louis School of Medicine 
Farlow Marty Indiana University 
Fitzpatrick Colleen Brigham and Women's Hospital-Massachusetts 
Flynn Gigi Washington University in St. Louis School of Medicine 
Fox Nick University College London 
Franklin Erin Washington University in St. Louis School of Medicine 
Fujii Hisako Osaka City University 
Gant Cortaiga Washington University in St. Louis School of Medicine 
Gardener Samantha Edith Cowan University, Perth 
Ghetti Bernardino Indiana University 
Goate Alison Icahn School of Medicine at Mount Sinai 
Goldman Jill Columbia University 
Gordon Brian Washington University in St. Louis School of Medicine 
Graff-Radford Neill Mayo Clinic Jacksonville 
Gray Julia Washington University in St. Louis School of Medicine 
Groves Alexander Washington University in St. Louis School of Medicine 
Hassenstab Jason Washington University in St. Louis School of Medicine 
Hoechst- Swisher Laura Washington University in St. Louis School of Medicine 
Holtzman David Washington University in St. Louis School of Medicine 
Hornbeck Russ Washington University in St. Louis School of Medicine 
Houeland DiBari Siri German Center for Neurodegenerative Diseases (DZNE) Munich 
Ikeuchi Takeshi Niigata University 
Ikonomovic Snezana University of Pittsburgh 
Jerome Gina Washington University in St. Louis School of Medicine 
Jucker Mathias German Center for Neurodegenerative Diseases (DZNE) Tubingen 
Karch Celeste Washington University in St. Louis School of Medicine 
Kasuga Kensaku Niigata University 
Kawarabayashi Takeshi Hirosaki University 
Klunk William (Bill) University of Pittsburgh 
Koeppe Robert University of Michigan 
Kuder-Buletta Elke German Center for Neurodegenerative Diseases (DZNE) Tubingen 
Laske Christoph German Center for Neurodegenerative Diseases (DZNE) Tubingen 
Lee Jae-Hong  Asan Medical Center 
Levin Johannes German Center for Neurodegenerative Diseases (DZNE) Munich 
Martins Ralph Edith Cowan University 
Mason Neal Scott University of Pittsburgh Medical Center 
Masters Colin University of Melbourne 
Maue-Dreyfus Denise Washington University in St. Louis School of Medicine 
McDade Eric Washington University in St. Louis School of Medicine 
Mori Hiroshi  Osaka City University 
Morris John Washington University in St. Louis School of Medicine 
Nagamatsu Akem Tokyo University 
Neimeyer Katie Columbia University 
Noble James Columbia University 
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Norton Joanne Washington University in St. Louis School of Medicine 
Perrin Richard Washington University in St. Louis School of Medicine 
Raichle Marc Washington University in St. Louis School of Medicine 
Renton Alan Icahn School of Medicine at Mount Sinai 
Ringman John University of Southern California 
Roh Jee Hoon Asan Medical Center 
Salloway Stephen Brown University-Butler Hospital 
Schofield Peter Neuroscience Research Australia 
Shimada Hiroyuki Osaka City University 
Sigurdson Wendy Washington University in St. Louis School of Medicine 
Sohrabi Hamid Edith Cowan University 
Sparks Paige Brigham and Women's Hospital-Massachusetts 
Suzuki Kazushi Tokyo University 
Taddei Kevin Edith Cowan University 
Wang Peter Washington University in St. Louis School of Medicine 
Xiong Chengjie Washington University in St. Louis School of Medicine 
Xu Xiong Washington University in St. Louis School of Medicine 
 
Supplementary Table 7. DELCODE study group 
Last Name First Affiliation 
Fuentes Manuel German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany;  
Charité – Universitätsmedizin Berlin, corporate member of Freie Universität 
Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 
Institute of Psychiatry and Psychotherapy, Hindenburgdamm 30, 12203 
Berlin, Germany 
Hauser Dietmar Charité – Universitätsmedizin Berlin, corporate member of Freie Universität 
Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 
Institute of Psychiatry and Psychotherapy, Hindenburgdamm 30, 12203 
Berlin, Germany 
Lindner Katja Charité – Universitätsmedizin Berlin, corporate member of Freie Universität 
Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 
Institute of Psychiatry and Psychotherapy, Hindenburgdamm 30, 12203 
Berlin, Germany 
Megges Herlind German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany; 
Charité – Universitätsmedizin Berlin, corporate member of Freie Universität 
Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 
Institute of Psychiatry and Psychotherapy, Hindenburgdamm 30, 12203 
Berlin, Germany 
Menne Felix German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany; 
Charité – Universitätsmedizin Berlin, corporate member of Freie Universität 
Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 
Institute of Psychiatry and Psychotherapy, Hindenburgdamm 30, 12203 
Berlin, Germany 
Peters Oliver  German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany; 
Charité – Universitätsmedizin Berlin, corporate member of Freie Universität 
Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 
Institute of Psychiatry and Psychotherapy, Hindenburgdamm 30, 12203 
Berlin, Germany 
Amthauer Holger Charité – Universitätsmedizin Berlin, corporate member of Freie Universität 
Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 
Department of Nuclear Medicine, Augustenburger Platz 1, 13353 Berlin 
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Kainz Christian Center for Cognitive Neuroscience Berlin (CCNB), Department of 
Education and Psychology, Freie Universität Berlin, Berlin, Germany 
Ehrlich Marie Charité – Universitätsmedizin Berlin, corporate member of Freie Universität 
Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 
Institute of Psychiatry and Psychotherapy, Hindenburgdamm 30, 12203 
Berlin, Germany 
Altenstein Slawek German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany 
Beuth Markus  Department of Psychiatry and Psychotherapy, Charité, Charitéplatz 1, 10117 
Berlin, Germany 
Langenfurth  Anika  Department of Psychiatry and Psychotherapy, Charité, Charitéplatz 1, 10117 
Berlin, Germany 
Priller  Josef  German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany;  
Department of Psychiatry and Psychotherapy, Charité, Charitéplatz 1, 10117 
Berlin, Germany 
Spruth Eike  Department of Psychiatry and Psychotherapy, Charité, Charitéplatz 1, 10117 
Berlin, Germany 
Villar Munoz Irene German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany 
Konstantina Kafali Department of Psychiatry and Psychotherapy, Charité, Charitéplatz 1, 10117 
Berlin, Germany 
Barkhoff Miriam German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-
Campus 1, 53127 Bonn, Germany 
Boecker Henning German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-
Campus 1, 53127 Bonn, Germany 
Daamen Marcel German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-
Campus 1, 53127 Bonn, Germany 
Faber Jennifer  German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-
Campus 1, 53127 Bonn, Germany 
Fließbach Klaus German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-
Campus 1, 53127 Bonn, Germany 
Frommann Ingo  German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-
Campus 1, 53127 Bonn, Germany 
Hennes Guido  German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-
Campus 1, 53127 Bonn, Germany 
Herrmann Gabi  German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-
Campus 1, 53127 Bonn, Germany 
Kalbhen Pascal  German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-
Campus 1, 53127 Bonn, Germany 
Kobeleva Xenia  German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-
Campus 1, 53127 Bonn, Germany 
Kofler Barbara German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-
Campus 1, 53127 Bonn, Germany 
Miebach Lisa German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-
Campus 1, 53127 Bonn, Germany 
Müller Anna German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-
Campus 1, 53127 Bonn, Germany 
Polcher Alexandra  German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-
Campus 1, 53127 Bonn, Germany 
Röske Sandra  German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-
Campus 1, 53127 Bonn, Germany 
Schneider Christine German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-
Campus 1, 53127 Bonn, Germany 
Schneider Anja  German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-
Campus 1, 53127 Bonn, Germany; Department for Neurodegenerative 
Diseases and Geriatric Psychiatry, University Hospital Bonn, Venusberg-
Campus 1, 53127 Bonn, Germany 
Spottke Annika  German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-
Campus 1, 53127 Bonn, Germany; Department of Neurology, University of 
Bonn, Venusberg-Campus 1, 53127 Bonn, Germany 
Vogt Ina German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-
Campus 1, 53127 Bonn, Germany 
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Wagner Michael  German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-
Campus 1, 53127 Bonn, Germany; Department for Neurodegenerative 
Diseases and Geriatric Psychiatry, University Hospital Bonn, Venusberg-
Campus 1, 53127 Bonn, Germany 
Westerteicher Christine  Department of Psychiatry and Psychotherapy, University of Bonn, 
Venusberg-Campus 1, 53127 Bonn, Germany 
Widmann Catherine Department of Psychiatry and Psychotherapy, University of Bonn, 
Venusberg-Campus 1, 53127 Bonn, Germany 
Wolfsgruber Steffen German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-
Campus 1, 53127 Bonn, Germany 
Yilmaz Sagik German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-
Campus 1, 53127 Bonn, Germany 
Brosseron Frederic German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-
Campus 1, 53127 Bonn, Germany 
Jessen Frank German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-
Campus 1, 53127 Bonn, Germany; Department of Psychiatry, University of 
Cologne, Medical Faculty, Kerpener Strasse 62, 50924 Cologne, Germany 
Bürger Katharina  German Center for Neurodegenerative Diseases (DZNE, Munich), Feodor-
Lynen-Strasse 17, 81377 Munich, Germany; Institute for Stroke and 
Dementia Research (ISD), University Hospital, LMU Munich, Feodor-
Lynen-Strasse 17, 81377 Munich, Germany 
Catak Cihan  Institute for Stroke and Dementia Research (ISD), University Hospital, 
LMU Munich, Feodor-Lynen-Strasse 17, 81377 Munich, Germany 
Coloma Andrews Lisa German Center for Neurodegenerative Diseases (DZNE, Munich), Feodor-
Lynen-Strasse 17, 81377 Munich, Germany 
Dichgans Martin  Institute for Stroke and Dementia Research (ISD), University Hospital, 
LMU Munich, Feodor-Lynen-Strasse 17, 81377 Munich, Germany; German 
Center for Neurodegenerative Diseases (DZNE, Munich), Feodor-Lynen-
Strasse 17, 81377 Munich, Germany; Munich Cluster for Systems 
Neurology (SyNergy), Munich, Germany 
Dörr Angelika  Institute for Stroke and Dementia Research (ISD), University Hospital, 
LMU Munich, Feodor-Lynen-Strasse 17, 81377 Munich, Germany 
Ertl-Wagner Birgit  Department of Radiology, University Hospital, LMU Munich, Germany 
Frimmer Daniela  Institute for Stroke and Dementia Research (ISD), University Hospital, 
LMU Munich, Feodor-Lynen-Strasse 17, 81377 Munich, Germany 
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Kreuzer  Max  Institute for Stroke and Dementia Research (ISD), University Hospital, 
LMU Munich, Feodor-Lynen-Strasse 17, 81377 Munich, Germany 
Markov Eva  Institute for Stroke and Dementia Research (ISD), University Hospital, 
LMU Munich, Feodor-Lynen-Strasse 17, 81377 Munich, Germany 
Müller Claudia  German Center for Neurodegenerative Diseases (DZNE, Munich), Feodor-
Lynen-Strasse 17, 81377 Munich, Germany 
ser Axel Department of Nuclear Medicine, University Hospital, LMU Munich, 
Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), 
Munich, Germany 
Schmid  
(form. Spreider) 
Jennifer Institute for Stroke and Dementia Research (ISD), University Hospital, 
LMU Munich, Feodor-Lynen-Strasse 17, 81377 Munich, Germany 
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Center, Gehlsheimer Str. 20, 18147 Rostock 
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Teipel Stefan  German Center for Neurodegenerative Diseases (DZNE), Rostock, 
Germany; Department of Psychosomatic Medicine, Rostock University 
Medical Center, Gehlsheimer Str. 20, 18147 Rostock 
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Kuder-Buletta Elke German Center for Neurodegenerative Diseases (DZNE), Tübingen, 
Germany 
Laske Christoph  German Center for Neurodegenerative Diseases (DZNE), Tübingen, 
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Supplementary Figure 1. Correlation matrices. Intercorrelations (multicollinearity) between AD biomarkers, 
SVD markers, age and sex. Grey boxes indicate “not available”. Abbreviations: AD = Alzheimer’s disease; P-tau 
= phosphorylated-tau181; SVD = small vessel disease; SVD score = total small vessel disease score; T-tau = total 
tau; WMHvol = white matter hyperintensity volume. 
 
Supplementary Text 1. CSF and PET markers 
CSF markers 
Aβ 40, Aβ 42, t-tau, and p-tau CSF measurements were analyzed locally (within each study) 
with study specific assays for DIAN (Araque Caballero et al., 2018), DELCODE (Jessen et al., 
2018), and UVCI (de Wilde et al., 2017). For the subgroup analysis we used the following cut-
offs for Aβ 42 (CSF) abnormality: < 496 pg/ml (DELCODE) (Jessen et al., 2018) and < 640 
pg/ml (UVCI) (Zwan et al., 2014). For DIAN no study-specific cut-off was available, thus we 
applied the more restrictive DELCODE threshold (< 496 pg/ml). 
PET markers 
Aβ [18F]-florbetapir (ADNI) or Aβ [18F]-florbetaben (SVCI) and tau [18F]AV-1451 PET 
measures were obtained. Details on PET acquisition and analysis are available for ADNI 
(http://adni.loni.usc.edu) and SVCI (Kim et al., 2018). For ADNI, we used the freesurfer-
derived global Aβ (PET) SUVR scores across the frontal, anterior-posterior cingulate, lateral-
parietal, and lateral-temporal gray matter regions with whole cerebellum as the reference region 
(provided by the ADNI-PET Core). For SVCI we used locally calculated global Aβ PET SUVR 
scores across 25 cerebral cortex regions with cerebellar grey matter as the reference region 
(Kim et al., 2018). For the subgroup analysis we used the following Aβ (PET) cut-offs for 
abnormality: Aβ [18F]-florbetapir > 1.11 (ADNI) (Landau et al., 2012) and Aβ [18F]-florbetaben 
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> 1.45 (SVCI) (Bullich et al., 2017). For both PET samples, we calculated an established global 
mean tau PET SUVR score (Maass et al., 2017). 
 
Supplementary Text 2. Processing of diffusion measures 
All diffusion images were processed with the same pipeline. After visual inspection to exclude 
major artefacts, raw diffusion images were pre-processed using the MRtrix v3.0 package 
(http://www.mrtrix.org) and the Functional Magnetic Resonance Imaging of the Brain software 
library (FSL), v5.0.10 (Smith et al., 2004). Noise and Gibbs ringing artefacts were removed 
(‘dwidenoise’, ‘mrdegibbs’ (Kellner et al., 2016); MRtrix) and images were corrected for 
subject motion and eddy current induced distortions (‘eddy_correct’; FSL). Conventional DTI 
measures, i.e. uncorrected fractional anisotropy (FAu) and mean diffusivity (MDu), as well as 
free water imaging measures, i.e. the free water corrected tissue measures, FAt and MDt, and 
the free water content (FW), were calculated as previously described (Duering et al., 2018). 
Global and voxel-wise alterations of diffusion measures were assessed on the skeleton of main 
white matter tracts, which was calculated using the tract-based spatial statistics pipeline (Smith 
et al., 2006) within FSL. For all samples, an FAt threshold ≥ 0.3 and a custom-made mask 
(Baykara et al., 2016) were used to exclude areas prone to CSF contamination, a crucial aspect 
in patient samples with brain atrophy (Berlot et al., 2014). 
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2.2 Study 2: Application of diffusion MRI markers 
The following section includes the research article entitled “Minor gait impairment despite 
white matter damage in pure small vessel disease”. The manuscript was published 2019 in 
Annals of clinical and translational neurology (Finsterwalder et al., 2019). 
Minor gait impairment despite white matter damage in pure small vessel disease 
Sofia Finsterwalder, MSc1 Max Wuehr, PhD2 Benno Gesierich, PhD1 Anna Dietze, BSc2 Marek 
J. Konieczny, MSc1 Reinhold Schmidt, MD3 Roman Schniepp, MD2,* and Marco Duering, 
MD1,* 
*contributed equally as senior authors 
1 Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Munich, Germany 
2 German Center for Vertigo and Balance Disorders DSGZ, Department of Neurology, University Hospital, LMU 
Munich, Munich, Germany 
3 Medical University of Graz, Department of Neurology, Graz, Austria 
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2.2.1 Abstract 
Objective: Gait impairment is common in patients with cerebral small vessel disease (SVD). 
However, gait studies in elderly SVD patients might be confounded by age-related 
comorbidities, such as polyneuropathy or sarcopenia. We therefore studied young patients with 
the genetically defined SVD CADASIL. Our aim was to examine the effects of pure SVD on 
single and dual task gait, and to investigate associations of gait performance with cognitive 
deficits and white matter alterations. 
Methods: We investigated single task walking and calculatory, semantic, or motoric dual task 
costs in 39 CADASIL patients (mean age 50 ± 8) using a computerized walkway. We obtained 
3 Tesla MRI and neuropsychological data on processing speed, the main cognitive deficit in 
CADASIL. Spatio-temporal gait parameters were standardized based on data from 192 healthy 
controls. Associations between white matter integrity, assessed by diffusion tensor imaging, 
and gait were analyzed using both a global marker and voxel-wise analysis.  
Results: Compared to controls, CADASIL patients showed only mild single task gait 
impairment, and only in the rhythm domain. The semantic dual task additionally uncovered 
mild deficits in the pace domain. Processing speed was not associated with gait. White matter 
alterations were related to single task stride length but not to dual task performance.  
Interpretation: Despite severe disease burden, gait performance in patients with pure small 
vessel disease was relatively preserved in single and dual tasks. Results suggest that age-related 
pathologies other than small vessel disease might play a role for gait impairment in elderly SVD 
patients. 
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2.2.2 Introduction 
Gait impairment and cognitive deficits are common symptoms in cerebral small vessel disease 
(SVD) and a major cause of loss of independence (Román et al., 2002; Chabriat et al., 2009). 
For mobility capabilities, both symptoms bear a high risk for falls and fractures, specifically in 
the elderly (Bridenbaugh and Kressig, 2015). Senile, vascular gait impairment in sporadic SVD 
patients has been characterized by a reduction of gait velocity (Rosano et al., 2006; Verghese 
et al., 2007; de Laat et al., 2010a; de Laat et al., 2011; Smith et al., 2015), reduction of stride 
length (Rosano et al., 2006; de Laat et al., 2010a; de Laat et al., 2011), and increased double 
support times (Rosano et al., 2006; de Laat et al., 2010a). However, the etiology of gait 
impairment in SVD is still debated. The traditional view holds that lesions in strategic white 
matter tracts have a detrimental effect on supraspinal locomotor control (Rosano et al., 2006; 
de Laat et al., 2010a; Loos et al., 2018; Van Der Holst et al., 2018). This view is challenged by 
studies showing that gait control can also be affected by age-related instability due to 
degenerative musculoskeletal impairments e.g. joint problems, sarcopenia or polyneuropathy 
(Bridenbaugh and Kressig, 2015). A complementary view is that cognitive deficits are a major 
cause of gait disturbances and falls (Montero-Odasso et al., 2012). The notion is based on 
experiments using cognitive dual-tasking, in which participants perform an attention-
demanding task while walking (Bayot et al., 2018). Gait performance deteriorates under this 
condition in healthy subjects (Theill et al., 2011) and especially in cognitively impaired subjects 
(Al-Yahya et al., 2011; Montero-Odasso et al., 2012; Muir et al., 2012; Doi et al., 2014; Smith 
et al., 2016). The underlying hypothesis is that walking, i.e. planning and execution of 
movements, postural control, motor coordination, and the secondary cognitive task compete for 
the same limited cognitive resources. While gait difficulties can be cognitively compensated 
during single task walking, this compensation mechanism is disrupted or limited by a secondary 
cognitive task. Thus, dual task walking can pronounce or even uncover gait deficits that are not 
obvious while walking only (Muir et al., 2012; Bridenbaugh and Kressig, 2015). 
Results of previous studies on gait impairment in SVD are based on sporadic SVD patients or 
individuals with mild cognitive impairment (MCI) aged 60 years or older (Rosano et al., 2006; 
Verghese et al., 2008; de Laat et al., 2010a; de Laat et al., 2011; Muir et al., 2012; Loos et al., 
2018; Van Der Holst et al., 2018). A potentially crucial limitation of these studies is the 
confounding by age-related co-pathologies, such as affected biomechanics, sarcopenia or 
disturbed sensory feedback (vision, proprioception). One approach to overcome these 
limitations is to explore the effect of dual-tasking on gait in a model disease of pure SVD 
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without confounding pathology. We therefore studied patients with cerebral autosomal 
dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a 
genetically defined, pure form of SVD. CADASIL is characterized by an early disease onset 
between 35 and 50 years (Chabriat et al., 2009). Conditions typically impacting on gait 
performance in elderly subjects, such as musculoskeletal constraints, joint abrasion, 
polyneuropathy, Alzheimer-type changes or other neurodegenerative pathology (Suttanon et 
al., 2012), and normal-pressure hydrocephalus (Armand et al., 2011) are uncommon in 
CADASIL patients. 
SVD-related white matter alterations can be assessed using diffusion tensor imaging (DTI). 
DTI scalar measures are sensitive markers for SVD progression (Zeestraten et al., 2016) and 
show a stronger association with gait decline than conventional SVD markers, such as white 
matter hyperintensities (WMH), lacunes, and microbleeds (Van Der Holst et al., 2018). 
The aim of the present study was to investigate the effect of pure SVD on single task and dual 
task walking. We hypothesized that (1) gait impairment in pure SVD would be most evident 
while dual task walking, (2) there is an association between processing speed, the main 
cognitive deficit in SVD, and gait, and (3) SVD-related white matter alterations (as assessed by 
DTI) are associated with gait performance. 
To our knowledge this is the first study analyzing spatio-temporal gait data in patients with pure 
SVD. Here, we combine most recent methods of gait recording, diffusion tensor imaging and 
analysis. 
2.2.3 Methods 
Subjects 
We included 39 CADASIL patients from an ongoing, prospective single-center study in 
Munich, Germany. CADASIL was confirmed by either molecular genetic testing (sequencing 
of the NOTCH3 gene) or by ultrastructural analysis of a skin biopsy (detection of 
pathognomonic granular osmiophilic material in vessel walls). Inclusion criteria were age ≤ 70 
years, absence of focal neurological deficits (e.g. paresis after stroke), absence of signs for 
polyneuropathy, available data for gait, neuropsychological testing, and MRI. All examinations 
were performed within two consecutive days. 192 age- and sex-matched healthy controls were 
recruited from local staff or by advertisement. In a standardized interview, none of the controls 
reported any auditory, vestibular, neurologic, cardio-vascular or orthopedic disorders. A short 
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physical examination was performed to exclude impairments in motor and sensory functions, 
coordination, balance, orientation, and short-term memory. All study participants had normal 
or corrected-to-normal vision. Leg length was measured in all subjects to be used as covariable 
in the statistical analysis. The study was performed in accordance with the Declaration of 
Helsinki and approved by the local ethics committee. Written informed consent was obtained 
from all subjects. 
Quantitative gait assessment 
Spatio-temporal gait performance was assessed using the electronic, pressure-sensitive 
GAITRite® carpet (CIR Systems, Havertown, USA) with a length of 670 cm and a sampling 
rate of 120 Hz. It was recorded under four different conditions similar to previously used 
experimental protocols (Beauchet et al., 2005; Theill et al., 2011; Montero-Odasso et al., 2012; 
Muir et al., 2012). Four trials were performed in each condition to increase the number of 
recorded gait cycles and thereby improve the reliability of gait parameters (König et al., 2014; 
Perera et al., 2016). In the first condition, subjects were asked to walk over the carpet with 
preferred speed (condition 1, single task). In the remaining three conditions, subjects were 
asked to perform dual tasks. In the first dual task condition, subjects performed a calculatory 
cognitive task while walking (condition 2, calculatory dual task), i.e. serial 7 task. Using this 
task, we tested the effect of a secondary, working memory task on gait (Lee and Kang, 2002). 
Next, subjects performed a semantic cognitive task while walking (condition 3, semantic dual 
task), i.e. a verbal fluency task. This task was used to test the effect of a semantic memory task 
on gait (Weiss et al., 2003). Finally, subjects performed a motoric, control task while walking 
(condition 4, motoric dual task), i.e. carrying an empty tray. Subjects were asked to prioritize 
the secondary task during walking. 
Each walk was started 150 cm in front of the carpet and continued for 150 cm beyond it in order 
to record steady-state locomotion. Gait parameters were recorded as the mean of the four trials 
within each condition. We selected eight gait parameters that have been reported to correlate 
with cognitive deficits (Verghese et al., 2007) and/or neuroimaging aspects of SVD (de Laat et 
al., 2010b). These parameters can be assigned to three different domains (Verghese et al., 
2008). Parameters assigned to the pace domain were (1) velocity (cm/s), (2) cadence 
(steps/min), and (3) stride length (cm). Parameters assigned to the rhythm domain were (4) 
double support phase (% of gait cycle when both feet simultaneously have ground contact) and 
(5) swing phase (% of gait cycle when one foot is in the air). Parameters assigned to the 
variability domain were (6) stride time variability (%), (7) stride length variability (%), and (8) 
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base of support variability (%). Variability was calculated as the coefficient of variation in 
percentage (CV = [standard deviation of parameter/mean of parameter] ´ 100). It represents the 
magnitude of stride-to-stride fluctuations within one gait parameter, with less variability 
suggesting higher gait automaticity and stability (Hausdorff, 2005). All gait parameters were 
calculated with respect to the left leg side. 
For analysis, we used single task walking performance and dual task costs, i.e. the relative 
difference between dual task walking and single task walking (dual task costs = ([dual task 
walking – single task walking]/single task walking) ´ 100). We assessed dual task costs in order 
to examine performance alterations under dual task walking in relation to single task walking.  
Gait parameters in the single task and dual task costs were standardized. We transformed raw 
data into z-scores by calculating means and standard deviations of 192 healthy controls (tested 
with the same gait protocol at our institution) separately for males and females in age ranges of 
20-39, 40-59, and 60-79 years. We used z-scores as an intuitive measure for effect size of 
differences between CADASIL patients and healthy controls. Negative z-values represent 
worse performance compared to controls. A z-value of 0 represents no difference between 
CADASIL patients and controls, i.e. norm performance. 
Neuropsychological assessment 
The Trail Making Test (TMT) is a paper-pencil test on executive functions, specifically mental 
flexibility and processing speed (Kortte et al., 2002). In TMT matrix A participants are asked 
to connect numbers presented at different locations on the sheet of paper from 1 to 25 in 
increasing order as quickly as possible. In TMT matrix B numbers and letters have to be 
connected alternately in increasing order. TMT raw test scores were transformed into age- and 
education-corrected z-scores based on normative data from the literature (Tombaugh, 2004). 
We pre-specified processing speed for cognitive function analysis, because it is the most 
prominently and often only affected cognitive domain in SVD (Peters et al., 2005). More 
specifically, we used a previously established compound score of processing speed (mean z-
score of TMT A and B), which has been shown to highly correlate with white matter alterations 
in SVD (Duering et al., 2011; Zieren et al., 2013; Baykara et al., 2016).  
Magnetic resonance imaging 
MRI scans of all CADASIL patients were acquired on a single 3.0 T Magnetom Verio scanner 
(Siemens Healthineers, Erlangen, Germany). The MRI protocol included 1 mm isotropic 3D-
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T1, 1 mm isotropic 3D fluid-attenuated inversion recovery (FLAIR), 2D-T2 and diffusion MRI 
sequences (30 diffusion directions; b-value 1000 s/mm2, 2 mm isotropic). Complete details on 
sequence parameters have been described previously (Duering et al., 2018). 
The following SVD lesions were quantified according to the STRIVE consensus criteria 
(Wardlaw et al., 2013) to enable a better interpretation of sample characteristics: WMH volume, 
lacune volume, and brain volume. Processing pipelines have been described previously 
(Duering et al., 2011; Tuladhar et al., 2015). All volumes were normalized for head size by the 
intracranial volume. 
Diffusion tensor imaging 
We used DTI to study the effect of white matter alterations on gait. DTI is a sensitive technique 
to characterize white matter microstructure by quantifying water diffusion in brain tissue 
(Nucifora et al., 2007). In SVD, the magnitude of diffusion in brain tissue is increased (increase 
in mean diffusivity, MD). To extract DTI measures, we performed the following processing 
steps: 
After visual inspection to exclude major artefacts, diffusion data were pre-processed using 
MRtrix v3.0 package (http://www.mrtrix.org) and the Functional Magnetic Resonance Imaging 
of the Brain software library (FSL), v5.0.10 (Smith et al., 2004). After noise and Gibbs ringing 
artefacts removal using ‘dwidenoise’ (Veraart et al., 2016) and ‘mrdegibbs’ (Kellner et al., 
2016) (MRtrix), images were corrected for subject motion and eddy-currents (‘eddy_correct’; 
FSL). Diffusion tensors and scalar diffusion measures were estimated using ‘dtifit’ (FSL). 
We analyzed the effect of both global and regional white matter alterations on gait. As a global 
measure for SVD-related white matter alterations, we calculated the peak width of skeletonized 
mean diffusivity (PSMD) (Baykara et al., 2016). PSMD is a fully automated SVD burden 
marker and sensitively captures global alterations in white matter integrity. We pre-specified 
PSMD as a marker for global white matter alterations, because it highly correlates with 
processing speed (Duering et al., 2011; Zieren et al., 2013) and outperforms other MRI based 
markers (such as WMH volume, lacune volume, and brain volume) in explaining clinical 
deficits (Baykara et al., 2016). PSMD was calculated with a publicly available script 
(http://www.psmd-marker.com).  
To analyze regional white matter alterations, we calculated voxel-wise MD values within major 
white matter tracts. We used the tract-based spatial statistics (TBSS) pipeline (Smith et al., 
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2006) within FSL with standard parameters and a fractional anisotropy standard template in 
Montreal Neurological Institute (MNI) space, provided by FSL. Rigorous checks were 
performed at each step of the pipeline. Finally, a custom mask was applied to exclude regions 
close to cerebrospinal fluid in order to avoid partial volume effects.  
Statistical Analyses 
Statistical analyses were performed in R (v3.4.1) (R Core Team, 2013). Wilcoxon signed-rank 
tests against zero were used to examine whether z-scores (representing differences between 
CADASIL and healthy controls) were significantly different from zero, i.e. from norm 
performance. We used non-parametric testing due to presence of non-normally distributed 
values in patients. 
The association between processing speed or global white matter alterations (assessed by 
PSMD) and gait performance was evaluated by multiple, linear regression models corrected for 
patients’ leg lengths. Gait parameters were used as dependent variables. Gait parameters, 
processing speed scores, and PSMD values were power transformed in case of non-normal 
distribution. P-values of multiple regressions and Wilcoxon signed-rank tests against zero were 
Bonferroni-corrected. Statistical significance level was set at 𝛼𝛼corr. < 0.05. 
Regional associations between white matter alterations (voxel-wise MD values as independent 
variables) and gait parameters (dependent variables) were performed using permutation test 
theory with a standard general linear model (‘randomise’; FSL). All linear models were 
corrected for leg length. The number of permutations was set at 5000. Significant voxels within 
the skeletonized MD maps were identified using threshold-free cluster enhancement with P < 
0.05, corrected for multiple comparisons. 
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Table 1. Sample characteristics 
 
 CADASIL 
n = 39 
Demographic characteristics  
Age, years 
mean (SD), [min, max] 
50.0 (8.1) 
[32.0, 62.0] 
Education, years, mean (SD) 10.8 (1.6) 
Female, No. [%] 27 [69] 
Cognitive scores 
TMT-Aa  
median (IQR), [min, max] 
-0.22 (1.31) 
[-8.62, 1.29] 
TMT-Ba,  
median (IQR), [min, max] 
-0.43* (2.58) 
[-12.66, 1.72] 
Processing speeda,  
median (IQR), [min, max] 
-0.55** (2.06) 
[-10.64, 1.36] 
Verbal fluencya 
median (IQR), [min, max] 
0.20 (1.39) 
[-1.83, 2.61] 
MMSE 
median (IQR), [min, max] 
30 (1) 
[27, 30] 
Imaging characteristics  
PSMD, 10-4 mm2/s 
median (IQR), [min, max] 
4.54 (2.32) 
[2.67, 9.21] 
Normalized WMHV, %, 
median (IQR), [min, max] 
4.40 (6.04) 
[0.09, 22.84] 
Normalized LV, % 
median (IQR), [min, max] 
0.01 (0.06) 
[0.00, 0.25] 
BPF, 
median (IQR), [min, max] 
 0.80 (0.06) 
[0.70, 0.87] 
 
aAge- and education-adjusted z-scores; ** Pcorr. < 0.01, * Pcorr. < 0.05; Wilcoxon signed-rank tests against zero. 
Abbreviations: BPF = brain parenchymal fraction; IQR = interquartile range; LV = lacune volume; MMSE = Mini-
Mental State Examination; PSMD = peak width of skeletonized mean diffusivity; TMT = Trail Making Test; 
WMHV = white matter hyperintensity volume. 
 
2.2.4 Results 
Sample characteristics 
Sample characteristics are provided in Table 1. CADASIL patients showed a high WMH lesion 
load (Fig. 1). Raw values of single task gait performance and dual task costs for CADASIL 
patients as well as for healthy controls are depicted in Table 2. 
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Figure 1. White matter hyperintensities in pure SVD. White matter hyperintensities on fluid-attenuated 
inversion recovery (FLAIR) images. (A) Subject with median lesion load. (B) Lesion frequency map superimposed 
onto the Montreal Neurological Institute 152 standard brain template. Abbreviation: L = left. 
 
Table 2. Raw values of single task walking and dual task costs in CADASIL and healthy 
controls 
 
§Median (interquartile range) [min, max]. Abbreviations: BoS CV = base of support variability; Cad = cadence; 
DSupp = double support; SLen = stride length; STime CV = stride time variability; SLen CV = stride length 
variability; Swing = swing phase; Vel = velocity. 
 
 
 CADASIL (n=39)  Healthy controls (n=192) 
        
 Single task  Dual task costs  Single task  Dual task costs 
   calculatory semantic motoric    calculatory semantic motoric 
Pace         
Vel§ 
cm/s 
115.0 (47.7) 
[56.8, 186.4] 
 -16.6 (24.8) 
[-59.3, 24.2] 
-17.4 (18.4) 
[-61.3, 14.8] 
-4.7 (19.5) 
[-47.6, 30.2] 
 113.6 (23.3) 
[74.5, 166.9] 
 -10.4 (17.2) 
[-39.7, 7.4] 
-7.6 (16.8) 
[-33.0, 16.4] 
3.9 (13.8) 
[-27.4, 27.5] 
Cad§ 
steps/min 
111.5 (15.6) 
[82.2, 138.1] 
 -8.7 (13.2) 
[-44.1, 13.9] 
-9.3 (15.8) 
[-41.4, 4.7] 
-0.2 (11.6) 
[-25.6, 15.7] 
 112.0 (13.0) 
[88.0, 132.4] 
 -5.3 (11.1) 
[-42.6, 9.9] 
-5.0 (13.3) 
[-25.3, 8.1] 
4.0 (7.7) 
[-12.4, 17.0] 
SLen§  
cm 
127.8 (26.9) 
[73.0, 181.5] 
 -7.6 (10.5) 
[-38.2, 13.6] 
-6.5 (12.5) 
[-33.7, 21.7] 
-2.5 (10.9) 
[-30.7, 13.0] 
 125.0 (16.0) 
[98.2, 157.2] 
 -3.6 (10.7) 
[-20.4, 5.0] 
0.5 (8.8) 
[-13.6, 9.4] 
0.9 (9.2) 
[-18.0, 10.6] 
Rhythm         
DSupp§  
% 
24.4 (5.7) 
[17.6, 34.4] 
 14.0 (18.4) 
[-12.1, 77.4] 
11.6 (14.5) 
[-4.1, 47.2] 
3.3 (12.8) 
[-10.1, 40.2] 
 21.3 (8.0) 
[13.0, 29.1] 
 5.0 (13.4) 
[-8.6, 912.8] 
4.7 (13.9) 
[-9.7, 45.2] 
-1.9 (12.9) 
[-12.3, 13.6] 
Swing§  
% 
37.8 (2.4) 
[31.1, 40.4] 
 -3.7 (4.9) 
[-30.3, 4.7] 
-2.5 (6.3) 
[-21.7, 3.5] 
-1.3 (4.0) 
[-17.8, 8.1] 
 39.1 (5.1) 
[35.0, 43.8] 
 -1.4 (3.4) 
[-16.9, 5.2] 
-0.2 (4.8) 
[-8.0, 6.2] 
0.4 (4.0) 
[-7.4, 6.4] 
Variability        
STime§  
CV % 
2.0 (1.4) 
[0.6, 7.8] 
 54.1 (147.4) 
[-78.3, 1005.0] 
47.9 (165.6) 
[-83.5, 750.0] 
-5.6 (62.3) 
[-67.4, 231.5] 
 1.7 (0.9) 
[0.8, 5.0] 
 94.3 (129.8) 
[-65.5, 1186] 
6.4 (15.1) 
[-8.1, 32.2] 
2.6 (61.1) 
[-75.8, 252.8] 
SLen§  
CV % 
2.0 (1.6) 
[0.6, 10.7] 
 91.1 (93.3) 
[-51.1, 503.8] 
81.0 (126.2) 
[-40.6, 425.2] 
11.6 (97.6) 
[-63.0, 351.4] 
 2.3 (1.3) 
[0.8, 6.1] 
 38.1 (110.2) 
[-50.6, 330.3] 
27.8 (71.5) 
[-56.5, 219.0] 
-6.5 (65.3) 
[-69.1, 127.4] 
BoS§  
CV % 
18.5 (11.0) 
[6.7, 57.0] 
 6.1 (63.2) 
[-60.2, 192.3] 
-0.1 (74.1) 
[-66.8, 410.5] 
-6.2 (71.5) 
[-56.0, 261.5] 
 20.1 (14.5) 
[6.8, 80.6] 
 -13.3 (98.3) 
[-94.2, 261.0] 
-24.8 (67.2) 
[-148.8, 233.3] 
-7.6 (64.7) 
[-77.5, 152.7] 
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Moderate single task gait changes in the rhythm domain 
Fig. 2 shows the gait profile of CADASIL patients during single task walking. CADASIL 
patients performed worse than controls in the rhythm domain, i.e. prolonged double support (z-
score median = -1.00; Pcorr. = 2.9´10-7) and shorter swing phase (z-score median = -0.94; Pcorr. 
= 7.4´10-9). Of note, effect sizes were only modest with about 1 standard deviation. Other 
domains than the rhythm domain were not affected. 
 
 
Figure 2. Single task walking. Median z-values in CADASIL (solid black line) and interquartile ranges (grey) 
for single task walking parameters. Negative values represent worse performance compared to healthy controls 
(dashed norm line). **Pcorr. < 0.01, Wilcoxon signed-rank tests against zero. Abbreviation: CV = coefficient of 
variation. 
Moderate increase in semantic dual task costs in the rhythm and pace domain  
The effects of the calculatory, semantic, and motoric task on gait performance were assessed 
by dual task costs (Fig. 3). Gait performance was predominantly changed by the semantic task. 
More specifically, semantic dual task walking pronounced deficits in the rhythm domain, which 
had already been affected in single task walking (i.e. prolonged double support, z-score median 
= -0.27; Pcorr. = 0.002, and swing phase, z-score median = -0.34; Pcorr. = 0.005). In addition, the 
semantic task uncovered deficits in the pace domain (i.e. reduced gait velocity, z-score median 
= -0.88; Pcorr. = 2.2´10-5, cadence, z-score median = -0.46; Pcorr. = 0.002, and stride length, z-
score median = -0.80; Pcorr. = 3.3´10-4). The calculatory task affected swing phase only (z-score 
median = -0.42; Pcorr. = 0.020). Again, effect sizes for dual task worsening were only moderate 
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(less than 1 standard deviation of the performance in healthy subjects). We did not find a dual-
tasking effect in the variability domain. As expected, the motoric task, which has been used as 
a control task, did not worsen gait. 
 
 
Figure 3. Dual task costs. Median z-values (dots) of different dual task costs in CADASIL patients. Negative 
values represent higher costs compared to healthy controls (dashed norm line). **Pcorr. < 0.01, *Pcorr. < 0.05,  
(*) Puncorr. < 0.05; Wilcoxon signed-rank tests against zero; bars depict the 95% confidence interval. Abbreviation: 
CV = coefficient of variation. 
 
Processing speed is not related to single task walking or dual task costs 
Compared with healthy controls, CADASIL patients performed significantly worse in speed-
dependent cognitive tests (Table 1). Also, processing speed was significantly associated with 
global white matter alterations (PSMD) (β = -0.78, R2adj. = 15.3%; Pcorr. = 0.008). To investigate 
whether processing speed impacts on gait performance, we examined associations with single 
task walking or dual task costs. There was no significant association with any single task 
parameter or dual task costs (all Puncorr. > 0.051, all Pcorr. > 0.410). 
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Global white matter alterations are associated with single task stride length 
Finally, we examined the impact of SVD-related white matter alterations on gait performance. 
First, we assessed the relationship between global white matter alteration (PSMD) and gait 
parameters. In the single task, higher PSMD was associated with shorter stride length (i.e. b = 
-0.21, R2adj. = 18.0%; Pcorr. = 0.030) (Supplementary Table 1). The association between PSMD 
and single task velocity was marginally significant (b = -0.18, R2adj. = 13.7%; Pcorr. = 0.090). 
There was no association with any other single task parameter or dual task costs (all Pcorr. > 
0.220). 
Regional effects of white matter alterations (MD) on gait performance were assessed using 
voxel-wise regression analyses. Higher MD values in the entire white matter skeleton were 
associated with shorter stride length and slower gait velocity in the single task (Fig. 4). 
Infratentorial white matter regions did not show significant voxels.  
Significant associations were also found for single task cadence, double support, stride time 
variability, and stride length variability. For these gait parameters, instead of the entire skeleton 
being significant, we found smaller significant clusters (Fig. 4). Still, for these smaller clusters 
there was no clear preference for specific white matter tracts, as individual clusters were 
distributed over the entire white matter. No significant voxels were found for swing phase or 
base of support. Importantly, similar to the global analysis using PSMD, no significant regional 
associations were found for dual task costs. 
2.2.5 Discussion 
We investigated the effect of pure, genetically defined SVD on gait while walking only (single 
task walking) and while performing a secondary cognitive or motoric task (dual task walking). 
We found that (1) despite severe brain lesions, single task gait performance in CADASIL 
patients was relatively preserved, with minor deficits only in the rhythm domain. (2) The 
semantic dual task aggravated gait rhythm deficits and uncovered pace deficits. (3) Cognitive 
impairment, i.e. processing speed deficits, in pure SVD did not worsen gait and (4) global white 
matter alterations affected single task stride length only. 
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Figure 4. Voxel-wise associations between mean diffusivity (MD) and single task walking. Axial slices of the 
white matter skeleton (green) superimposed onto the Montreal Neurological Institute 152 standard brain template. 
Depicted are significant associations (red) after correction for multiple comparisons. Abbreviations: CV = 
coefficient of variation; L = left.  
Gait performance of pure SVD patients with severe white matter alterations differed only 
slightly from that of healthy controls, i.e. around one standard deviation in the rhythm domain. 
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Dual task walking, which has been used to uncover or pronounce gait deficits (Bridenbaugh 
and Kressig, 2015) caused a moderate deterioration of the rhythm features and unmasked gait 
abnormalities in the pace domain that were not present during single task walking. Interestingly, 
we did not find an association between cognitive performance (i.e. processing speed) during 
neuropsychological testing and gait performance in our sample. Our results thus suggest that 
severe SVD alone and its effect on cognition might only play a minor role in causing gait 
impairment. In elderly, sporadic SVD patients, the combination with other age-related 
pathologies might be decisive for gait decline. One might speculate that joint problems, 
sarcopenia and reduced sensory input are therefore more promising targets for prevention and 
rehabilitation of gait deficits in the elderly (Bridenbaugh and Kressig, 2015). For instance, 
treatment for sarcopenia could include physical exercise, balance training, and protein 
supplementation to support muscle gain (Naseeb and Volpe, 2017). 
Affected gait domains in pure SVD 
Although only moderate, differences in gait performance between pure SVD patients and 
healthy controls were detectable in the rhythm domain while single task walking. Changes in 
gait rhythm indicate difficulties in keeping balance and have been shown to correlate with SVD 
markers, like WMH (Rosano et al., 2006). 
Semantic dual-tasking pronounced gait deficits in the rhythm domain and additionally 
uncovered deficits in the pace domain, suggesting that brain networks that control rhythm and 
pace are interlinked with networks for the performance of the verbal fluency task. Control of 
gait rhythm and pace and the semantic task seem to compete for the same cognitive resources 
resulting in higher dual task costs. This is in line with previous studies showing that verbal 
fluency dual tasks resulted in reduction in gait velocity in community-dwelling older adults 
(Smith et al., 2015), in individuals with MCI and Alzheimer’s disease dementia (Muir et al., 
2012). 
However, we did not find an effect of single or dual task walking on the variability domain in 
pure SVD patients indicating steady gait performance in all conditions. Gait variability has been 
described as a sensitive marker of dynamic gait stability and is an established parameter in fall 
risk assessment (Montero-Odasso et al., 2012). It seems that our sample of pure SVD patients 
was able to engage enough cognitive resources to compensate increasing variability from stride 
to stride, even while cognitive dual-tasking. 
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Ultimately, comparing affected gait domains or variables between studies with different cohorts 
is difficult, not only because of age differences and accompanying comorbidities in the study 
samples, but also because of the number and kind of examined gait variables (i.e. only velocity 
in most studies), and differences in secondary cognitive or motor tasks while walking. An 
agreement of standardized dual task methodologies is crucial in future research to further study 
gait impairment in SVD or neurodegenerative diseases. 
Differential effects of secondary, cognitive tasks 
In our sample of relatively young, pure SVD patients, the semantic (verbal fluency) dual task 
worsened gait more than the calculatory (serial 7) dual task. Some studies investigated the effect 
of type and complexity of the secondary tasks on dual task walking (Beauchet et al., 2005; 
Montero-Odasso et al., 2012; Muir et al., 2012; Walshe et al., 2015). Contrary to our results, it 
has been shown that the serial 7 task generates greater cognitive load than verbal fluency tasks 
in frail, older adults and subjects with MCI and Alzheimer’s disease, resulting in worse gait 
performance in the calculatory than the semantic task. A possible explanation for this difference 
with previous studies might be the typical cognitive profile in SVD, with deficits predominantly 
in processing speed. Verbal fluency is a semantic memory task imposing substantial demands 
upon processing speed during retrieval from semantic long-term memory. 
Effect of processing speed on gait 
Other than expected, we did not find an association between processing speed deficits and 
single task gait or dual task costs in pure SVD. Cognitive deficits, beside white matter 
alterations, are thought to be an important factor for gait disturbances, e.g. as shown in frail 
older adults, individuals with MCI, and demented patients while single task and dual task 
walking (Theill et al., 2011; Donoghue et al., 2012; Martin et al., 2012; Montero-Odasso et al., 
2012; Muir et al., 2012; Doi et al., 2014; Ghanavati et al., 2018). Yet, the effect of cognitive 
impairment on single and dual task gait has not been examined specifically in SVD. Our results 
in pure SVD patients suggest that cognitive deficits related to SVD do not worsen gait. Of note, 
none of our subjects was demented and thus we cannot exclude a detrimental effect of cognition 
on gait in late disease stages. Generalizability of existing study results about the relation 
between cognition and gait is limited, as tests used to measure processing speed or executive 
function vary between studies. Also, examined samples are considerably older than ours and 
the presence of age-related pathologies was not always systematically assessed or excluded. 
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The possibility remains that in previous studies associations between cognitive deficits and gait 
were at least in part driven by age-related comorbidities. 
Effect of white matter alterations on gait 
Correlation analyses revealed significant associations between SVD-related white matter 
alterations measured by DTI and reduced stride length and marginally velocity in pure SVD 
patients. The same parameters were affected in sporadic SVD patients with strategic brain 
lesions related to gait deficits (de Laat et al., 2010a; Van Der Holst et al., 2018). Using the 
voxel-wise analysis, we found no indication for regional effects or spatial heterogeneity. 
Instead, we found a rather global effect of supratentorial white matter alterations on pace 
parameters, i.e. on stride length and velocity, but not on cadence. In line with a study by de Laat 
et al. (2010a) only few voxels with higher MD were related to a lower cadence, suggesting that 
the control of cadence is less affected by white matter alterations than other pace parameters. 
Thus, white matter alterations might predominantly influence spatial characteristics of stepping 
like stride length. Temporal pace maker regions in the locomotor network, such as the cerebellar 
locomotor regions, do not appear to be affected in pure SVD.  
Limitations 
Some limitations need to be considered. First, we did not obtain MRI in our control group, 
therefore subclinical SVD cannot be excluded in our clinically healthy sample. Second, while 
the examination of eight different spatio-temporal gait variables allowed precise description of 
gait performance, correcting for multiple comparisons is accompanied by a loss of statistical 
power. Third, our results are based on cross-sectional data, which does not allow to draw 
conclusions on causality. While our sample of pure SVD patients was relatively small, it 
enabled to detect subtle differences between groups and provided the unique opportunity to 
study the effects of pure SVD. 
Conclusion 
Despite severe brain lesions in genetically defined, pure SVD patients, gait performance was 
relatively preserved. Differences between pure SVD patients and healthy controls in single task 
walking and dual task costs were only moderate. Neither processing speed performance nor 
white matter alterations were associated with dual task costs. We speculate that other age-
related morbidities affecting the brain or other relevant organ systems, such as 
neurodegeneration, pharmacotherapy, sarcopenia, musculoskeletal disease, or polyneuropathy 
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contribute towards gait impairment in elderly people. These factors should be considered in 
future research, as well as in new strategies for intervention and rehabilitation. 
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2.2.9 Supplementary material 
Supplementary Table 1. Linear regressions with global white matter alterations (PSMD) in 
the single task 
Regressor 
Single task 
b Puncorr. Pcorr. R2 adj. 
[%] 
Pace     
Vel -0.176 0.01 0.09 13.7 
Cad -0.148 0.08 0.65 5.5 
SLen -0.207 0.00  0.03* 18.0 
Rhythm     
DSupp -0.185 0.08 0.62 5.7 
Swing -0.190 0.33 1.00 0.0 
Variability     
STime CV -0.273 0.03 0.24 9.7 
SLen CV -0.192 0.04 0.22 8.5 
BoS CV  -0.027 0.84 1.00 0.0 
 
*Pcorr. < 0.05; Linear regressions corrected for leg length. Abbreviations: BoS CV = base of support variability; 
Cad = cadence; DSupp = double support; SLen = stride length; SLen CV = stride length variability; STime CV = 
stride time variability; Swing = swing phase; Vel = velocity. 
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3. GENERAL DISCUSSION 
The current thesis aimed at, first, clarifying the contribution of SVD and AD to diffusion MRI 
alterations (Study 1), and, second, applying diffusion measures as SVD markers to study gait 
impairment in pure SVD (Study 2).  
In the following sections, main findings in Study 1 and 2 and their key implications within and 
across studies are summarized. Directions for future research with a focus on advanced 
diffusion MRI are pointed out. 
 
3.1 Main findings 
This thesis comprises two articles, on the validation (Study 1) and application (Study 2) of 
diffusion MRI markers of SVD in gait research: Study 1: “Small vessel disease rather than 
Alzheimer’s disease determines diffusion MRI alterations in memory clinic patients” and Study 
2: “Minor gait impairment despite white matter damage in pure small vessel disease”. 
3.1.1 Diffusion measures as valid markers for cerebral small vessel disease 
The major findings in Study 1 are that, first, diffusion alterations (free water uncorrected DTI 
measures and FW) were consistently associated with SVD markers, even in samples with AD 
as the clinically predominant disease. The effect of AD biomarkers on diffusion measures was 
considerably smaller and outweighed by SVD. Second, differential effects of SVD and AD 
markers on measures from free water imaging were not observable. Results were remarkably 
consistent across memory clinic samples, indicating high generalizability of the findings. Our 
findings validate diffusion measures as markers of SVD. 
3.1.2 Minor gait impairment despite severe white matter alterations in pure cerebral small 
vessel disease 
The major findings of Study 2 are that, first, despite severe white matter alterations, gait 
impairment was only mild in pure SVD patients and, second, cognitive deficits were not 
associated with gait performance in our sample. Our findings indicate that the clinical notion 
of isolated white matter alterations being a major factor of gait impairment should be 
reconsidered. 
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3.2 Key implications 
The main results of Study 1 and 2 have important implications for both clinical practice and 
research on SVD and gait impairment. 
3.2.1 The value of diffusion MRI markers of cerebral small vessel disease 
Despite the wide use of diffusion measures as markers of subtle white matter alterations, their 
underlying pathology has so far been largely unknown. The results of Study 1 indicate that 
diffusion measures are more sensitive for SVD pathology than for AD pathology. This finding 
underlines the value of diffusion measures as markers of SVD and their superiority compared 
to conventional MRI markers. 
Diffusion MRI markers outperform conventional MRI markers of SVD, such as WMHs and 
lacunes, (see section 1.2) for several reasons. First, diffusion MRI markers provide a more 
detailed evaluation of the underlying white matter changes by detecting even subtle and gradual 
alterations invisible on conventional MRI. In contrast, conventional MRI markers typically 
coarsely dichotomize tissue into ‘normal’ and ‘abnormal’ (ter Telgte et al., 2018). Second, 
diffusion MRI markers show higher associations with SVD-related clinical deficits, such as 
reduced processing speed, than conventional MRI markers (Tuladhar et al., 2015; Baykara et 
al., 2016). Third, in contrast to conventional MRI markers, diffusion markers are robust and 
can be calculated fully automated (Konieczny et al., 2020). Therefore, diffusion measures 
should be used in studies to characterize SVD burden. 
The results of Study 1 imply that clinicians should always consider SVD as the origin of 
diffusion alterations in patients with mixed disease. Being aware of the underlying pathology 
of diffusion alterations may improve diagnosis, disease monitoring, prognosis, and may allow 
the application of potential therapeutic interventions to reduce dementia incidence, for instance, 
through control of vascular risk factors (Satizabal et al., 2016; Iadecola et al., 2019). Similarly, 
researchers using diffusion MRI markers may now draw conclusions not only on the effects of 
white matter alterations in general, but also on the vascular rather than neurodegenerative 
etiology. More specifically, studies investigating associations between diffusion MRI markers 
and clinical deficits may shed more light on the relation between SVD-related white matter 
alterations and symptoms, as e.g. shown in Study 2 on gait impairment in SVD. In clinical trials, 
researchers may now effectively stratify populations according to SVD burden based on 
diffusion MRI markers. 
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3.2.2 The need to account for multiple age-related pathologies when studying gait 
impairment in the elderly 
Results from Study 2 in pure SVD patients (CADASIL) suggest that SVD-related white matter 
alterations, in the absence of comorbidities, may not be as important for gait decline as 
previously thought (de Laat et al., 2010; Rosario et al., 2016; Pinter et al., 2017; Loos et al., 
2018; Van Der Holst et al., 2018). Instead, other age-related pathologies on the brain, or on 
relevant organ systems, independent of SVD, may be crucial for gait disturbances in the elderly. 
For instance, sarcopenia is considered a key factor for the reduction of physical performance 
including reduced gait speed (Cruz-Jentoft et al., 2019; Keller, 2019). Despite being very 
common in the elderly, sarcopenia is frequently underreported and underdiagnosed (Keller, 
2019). Furthermore, several studies show that polyneuropathy affects locomotion (Erdmann et 
al., 2007; Hoffman et al., 2015; Hanewinckel et al., 2016). In a large population-based sample, 
elderly subjects who were diagnosed with definite or probable polyneuropathy differed around 
one standard deviation in global gait performance, i.e. average across several gait parameters, 
from subjects without polyneuropathy (Hanewinckel et al., 2016). Participants with definite 
polyneuropathy were more likely to fall resulting in injury. Importantly, similar to sarcopenia, 
polyneuropathy is often overlooked. About half of the participants with polyneuropathy were 
newly diagnosed in the aforementioned study (Hanewinckel et al., 2016). Thus, undetected 
comorbidities may affect gait in sporadic SVD. 
Complementary, the interaction between SVD and age-related comorbidities may be decisive 
for gait performance. Gait disturbances related to infratentorial or peripheral constraints, e.g. 
sarcopenia or polyneuropathy, may not manifest, if intact white matter networks allow for 
supratentorial compensation (Schmid et al., 2013). Yet, this compensation mechanism may be 
disrupted by SVD or neurodegenerative disease resulting in pathologic gait. This supratentorial 
compensation theory would explain why other studies found an effect of SVD on gait 
performance in elderly subjects, while we observed no such effect in pure SVD, in the absence 
of comorbidities. Gait impairment in sporadic SVD patients may be due to disrupted 
compensation of comorbidities and not primary due to SVD-related white matter alterations. 
Taken together, studies indicate that aging affects the integrity of the central and peripheral 
nervous system, which is required for normal gait. Therefore, researchers should be aware of 
multiple confounding factors of aging and their possible interaction with SVD when studying 
gait impairment in the elderly. 
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3.3 Future directions 
Future studies on diffusion MRI markers and gait impairment may focus on methodological 
improvements as suggested in the following sections. 
3.3.1 Advanced diffusion MRI 
Diffusion MRI markers of SVD may be further improved by more elaborated MRI acquisition, 
such as multi-shell diffusion imaging, i.e. using more than one diffusion weight, and more 
advanced diffusion modelling than DTI or free water imaging (Nir et al., 2019). Advanced 
diffusion models include e.g. diffusion kurtosis imaging (DKI) and neurite orientation 
dispersion and density imaging (NODDI). DKI quantifies the deviation of diffusion processes 
from normal distribution. Less normally distributed diffusion indicates more complex white 
matter structure and thus higher tissue integrity. NODDI is a three-compartment model, similar 
to the free water model, but includes compartments of restricted extracellular and intracellular 
water, besides the free water compartment. Only recently, our group has shown that measures 
from multi-shell DKI and NODDI outperformed DTI measures in explaining cognitive deficits 
in SVD (Konieczny et al., 2020). Importantly, these advanced diffusion measures are thought 
to be more sensitive to earliest subtle white matter alterations than simple DTI measures 
facilitating the detection of the clinically highly relevant group of early stage SVD patients 
(Konieczny et al., 2020). It should be noted that increasing model complexity requires higher 
computational resources than simple DTI measures. Nevertheless, future studies could 
investigate the effect of SVD and AD on advanced diffusion measures and explore differential 
effects on the diffusion signal. 
As described above, diffusion measures are common MRI markers for focal white matter 
alterations in the brain tissue. However, diffusion-based measures can also be obtained within 
large-scale structural brain networks, which may better capture disease burden than focal 
markers. Diffusion-based measures reflect brain network integrity, i.e. integrity of white matter 
tracts connecting different brain areas. In order to calculate network markers, first structural 
networks need to be constructed using tractography based on DTI or more elaborated methods 
such as constrained spherical deconvolution (Tournier et al., 2004; Jeurissen et al., 2014). Once 
networks are constructed, graph analysis allows for quantification of network properties 
(Hagmann et al., 2007). Graph analysis conceptualizes the brain as a network, consisting of 
nodes (brain regions) and edges (connections between brain regions). From nodes and edges, 
various network measures can be calculated. For instance, several studies in SVD patients 
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reported decreased network efficiency, i.e. less efficient parallel information transfer in the 
whole network, and a decrease in the number of connections and strength of connectivity 
(Lawrence et al., 2014; Tang et al., 2015; Tuladhar et al., 2016; Tuladhar et al., 2017). 
Furthermore, a recent study reported that disorganizations of highly interconnected regions 
within structural networks contribute to cognitive impairment in SVD (Tuladhar et al., 2017). 
To date, diffusion-based measures of structural network integrity are not specific for SVD, but 
may also be related to network alterations in e.g. AD (Reijmer et al., 2015). Therefore, future 
studies should further investigate measures from structural network connectivity as markers for 
SVD. 
3.3.2 New strategies in studying gait 
Results from gait studies in the elderly can barely be compared, not only due to deficits in 
accounting for age-related instability and comorbidities, but also due to wide variations in gait 
protocols and gait analysis. This lack of consistency hampers progress in understanding the 
mechanisms of gait impairment and possible intervention strategies. Therefore, future studies 
should include comprehensive clinical examinations (identifying co-pathologies), agree on the 
kind of gait assessment (automatized and/or observational), specify gait parameters 
(quantitative and/or qualitative), and harmonize possible dual-task protocols (type of dual-task, 
control condition). Also, statistical analyses should include confounding factors of aging. 
Standards in gait assessment may facilitate comparability and interpretation of results.  
Our results on gait performance in pure SVD patients challenge the view that isolated white 
matter alterations in pure SVD, in the absence of comorbidities, are a major cause of gait 
impairment. By studying relatively young CADASIL patients, we were able to minimize 
confounding factors associated with aging and comorbidities. However, the effect of SVD on 
gait performance should be confirmed in younger sporadic SVD patients (less than 60 years). 
Furthermore, future studies should investigate possible interactions between SVD and age-
related comorbidities and explore whether SVD disrupts supratentorial compensation of e.g. 
sarcopenia (see 3.2.2 for the supratentorial compensation theory).  
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3.4 Conclusion 
Diffusion measures (free water uncorrected DTI measures and FW) are valid markers for SVD-
related white matter alterations. Advanced diffusion MRI and diffusion-based network analysis 
may further improve sensitivity and accuracy of markers for SVD.  
Diffusion MRI markers provide new insight into the effect of SVD burden on gait impairment: 
Severe white matter alterations as assessed by diffusion MRI markers had only mild effect on 
gait performance in pure SVD, in the absence of comorbidities. Harmonization of gait studies 
may further clarify the role of SVD in gait impairment.  
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